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Abstract
Prediction of T-cell Epitopes for Cancer Therapy
by
Arjun Arkal Rao
The human immune system can identify malfunctioning, damaged, or infected cells
within the body. The integrity of nucleated cells is communicated to the immune system through
short peptides which they display on their exterior using MHC proteins. Mutated peptides
produced in cancer cells due to single nucleotide events, short insertion or deletion events, or
due to large chromosomal rearrangements can help the immune system identify tumor cells
as threats. Adoptive T-cell and Vaccine-based therapies that stimulate autologous T-cells to
treat a patient’s disease are more specific than standard chemo- and radiotherapies because they
directly target tumor-specific mutations. They also potentially protect the body from recurrence
of the tumor due to their unique memory potential. However, T-cells are often perceptive to
only those cells originating from the patient’s body, making this a personalized treatment for
the disease. Rapid identification of tumor neoepitopes in a patient diagnosed with cancer will
greatly reduce the time taken to develop a personalized therapy.
This thesis primarily covers ProTECT, a computational workflow for the Prediction
of Epitopes for Cancer Therapy. ProTECT is an automated, scalable, and reproducible end-
to-end pipeline that processes patient sequencing data to produce a ranked list of neoepitopes
of therapeutic significance. ProTECT also attempts to predict the state of the MHC presen-
tation pathway in the tumor, and the tumor response to immunotherapies based on previously
ix
published immune signatures. I describe ProTECT and demonstrate its features using a cohort
of 326 Prostate Adenocarcinoma patients. I then demonstrate its clinical utility through the
identification of a neoepitope arising from a hotspot mutant in pediatric Neuroblastoma.
To enable ProTECT, I worked on two auxiliary projects, Toil and TransGene. Toil is
a workflow manager developed at the Genomics Institute at UCSC, and is the backbone of the
ProTECT workflow. I spent some of my time at UCSC working on enhancing the efficiency of
Toil workflows. TransGene is a tool I wrote that translates genomic variants (single nucleotide,
short insertions and deletions, and fusion genes) into peptides that are compatible with existing
peptide:MHC binding affinity predictors. These methods are also included in this thesis.
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Chapter 1
Introduction
1.1 Introduction
Cancer is one of the leading causes of human deaths worldwide. An estimated 1.6 million new
cases of cancer will be diagnosed in 2015 with about 590,000 deaths resulting from various
forms of the disease [107]. Mortality rates for 2013 recorded by the Center for Disease Control
show cancer as the second leading cause for death in the US, trailing behind Heart Disease
by a very small margin [59]. The prognosis of the cancer depends on the tissue of origin; for
instance, brain cancers have poorer prognoses than lung cancers. The standard treatment for
cancers include surgical resection of the tumor (if possible), followed by chemo- or radiation
therapy, which are well known to have adverse acute, and chronic side effects.
Chemotherapy is a treatment regimen that uses chemical agents to destroy cancer
cells. The chemicals destroy rapidly dividing cells, a characteristic of cancers, via programmed
cell death or apoptosis [76, 42]. Certain tissues in the body also have high cell division rates,
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such as the hair follicles or cells of the gastrointestinal tract, are adversely affected during
chemotherapy [4]. Radiation therapy uses ionizing radiation to destroy cancerous cells. Ionizing
radiation irreversibly damages DNA leading to cell death via apoptotic pathways. Radiation
therapy is administered using an external source of radiation such as an X-ray generator [47],
or using radioactive isotopes that operate from within the patient’s body [101]. While both
methods are carefully administered in order to target the radiation to the tumor, healthy cells in
the vicinity of the tumor can get caught in the path of the X-rays and undergo cellular damage
along with the target.
Both chemo- and radiation therapies are prone to damaging healthy, normal cells in
the patient. Chemotherapy is commonly associated with alopecia due to cellular damage in
hair follicles, nausea due to irritation caused in the gastrointestinal mucosa. Radiation therapy
has more localized effects since it is targeted directly at the tumor as compared to systemic
chemotherapy. Common side effects of radiation therapy include muscle soreness, swelling,
long-term muscle fibrosis, and even secondary cancers due to the cellular damage. This is a
serious drawback to these therapies, especially in the cases of brain cancers, and in all pediatric
cancers, where collateral damage of healthy cells could lead to physical or cognitive disabilities.
The body’s in-built defense mechanism, the immune system, is designed to protect the body
from threats at a cellular and sub-cellular level, such as viral infection, by selectively attacking
the threat with minimal damage to self-tissue. It seems logical that this system should also
detect cancer cells in the body as they pose a threat to the well-being of the body.
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1.2 Cancer and the immune system
Almost all cells in the body communicate with the immune system using cell-surface class I
Major Histocompatibility Complex (MHC) proteins. During the process of recycling old pro-
teins – or nascent proteins that were formed in the cell with errors in their amino acid sequence
– into amino acids, cells generate short fragments of the proteins that are processed and dis-
played to the immune system via these MHCI molecules. The immune system is constantly on
the lookout for cells displaying “non-self” peptides on MHCI molecules. Since all cells contain
the same genetic information, a cell displaying peptide from a protein not encoded within that
genetic information is either malfunctioning or infected by a microorganism that is producing
it. Both scenarios are detrimental to the body, and thus the immune system marks such cells for
destruction [78].
Mutations in cellular DNA can arise when the replication machinery in the cell is
compromised, as in the case of cancers. Mutations occurring in the coding regions of the DNA
can have various effects on the final protein product. Mis-sense point mutations, short insertions
or deletions, and fusion gene events in the DNA can all give rise to abnormal proteins that aren’t
seen in healthy, normal cells. These mutations often alter the function of the protein, render
them inactive, or make them constitutively active. All three effects are seen in cancer and can
drive the cancer towards a more aggressive form. Cancers also have mutations accumulated
over time that don’t contribute towards progression (passenger mutations). Mutated cancer-
specific proteins are potentially non-self molecules and the immune system is programmed to
destroy cells displaying such peptides on MHCI molecules. Hence MHCI displayed peptides
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in cancer cells are ideal targets for the specific, precise killing of tumor cells. To understand
exactly how the immune system would target these events, and how cancer cells can evade the
immune system, we first need to look into how the immune system functions.
1.3 Innate and Adaptive Immunity
The immune system is broadly classified into two subsystems, namely the innate, and
the adaptive immune systems. The innate immune system comprises of natural barriers to
pathogenic infiltration such as skin and mucosal surfaces, and the complement system, which
mainly protects the body from bacterial infection. Natural killer cells (NK cells) detect and de-
stroy cells displaying low or no cell surface protein MHCI, which is a common consequence of
viral infections. In fact, they were first detected back in 1975 by their ability to lyse tumor cells
that were MHC deficient, without prior stimulation [46]. The innate immune system provides
immediate non-specific response to infection and is an ancient system that is seen in one guise
or another in almost all forms of life. The adaptive immune system is more specialized and takes
longer to respond to an infection. However, it is more potent and can potentially remember a
pathogen and react immediately to future infections.
Dendritic cells are specialized phagocytic cells that act as a link between the innate
and adaptive immune responses. Dendritic cells sense pathogenic microorganisms in tissues
through cell-surface and intracellular receptors. Upon detecting a pathogen, they are activated
and process pathogen-derived proteins into smaller fragments for T cell activation. Activated
dendritic cells migrate to the lymph nodes and recruit T cells by presenting them with pathogen
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derived antigens displayed on MHCI and MHCII molecules, and the required co-stimulatory
signals [7, 100, 109]. A subset of T Cells can subsequently activate B cells, increasing the
potency of the adaptive immune response.
The adaptive immune system is a complex interaction between T cells and B cells,
set in motion by the disease-causing agent. T-Helper cells (also called CD4+ or just CD4 T
cells due to cell surface expression of CD4 protein) are activated by pathogen-derived peptides
presented to them via MHCII molecules on dendritic cells. Their primary role involves the
modulation of the adaptive immune response - activation of B cells and Cytotoxic T cells at
first, and inhibition of immune activity after the threat has been neutralized [99, 123]. Cytotoxic
T cells (also known as killer T cells, or CD8+ or CD8 cells due to expression of CD8 surface
protein) are activated by pathogen-derived peptides presented to them on MHCI molecules.
Activated CD8 cells detect specific antigenic peptides presented on infected cells via MHCI
and induce cell death by depositing perforin and granzyme molecules into the infected cells
[10, 77, 112]. It is important to mention that normal, healthy tissue graft from another individual
could contain “foreign” MHC molecules, MHC molecules not produced in the self-genome.
These foreign MHC molecules would be detected by T-cells as foreign, and be rejected by the
system even if they were displaying a self-peptide.
B cells detect antigen via surface bound antibodies (also known as B-cell receptors).
Receptor bound antigen is endocytosed and processed via the MHCII pathway. Helper-T cells
detect MHCII presented antigens on B cells and can activate the presenter cell by providing the
required co-stimulation. B cells can be activated by an alternate mechanism that does not require
T cells, however that is not discussed here. T cell-activated B cells undergo rapid proliferation
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after activation during which they also undergo selection to produce B cells that bind to antigen
with high specificity. Activation of B cells also induces class switching which allows B cells
to produce secreted antibodies that aid in the phagocytic activity of macrophages and dendritic
cells. Figure 1.1 describes the adaptive immune response after activation of a dendritic cell.
Figure 1.1: The adaptive immune response begins with the activation of a dendritic cell. Acti-
vated CTLs and NK cells directly attack the infected cell. T-Helper cells interact with CTLs,
B-cells, and other T-Helper cells. B cells produce antibodies which enable phagocytes to sense
the infected cell. Figure obtained from Lambotin, et.al., Nature Reviews Microbiology [64] and
modified to retain only relevant information.
While B cells are highly effective at clearing out infections, they are limited by the
requirement of cell-surface or secreted antigen for their action. In cancers, there can be a vast
number of mutations which alter the sequence of proteins produced by the tumor. However, few
(if any) of these mutations are present in the extracellular domains of cell-surface proteins and
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thus the action of B cells is limited. T cells, on the other hand, can detect changes in intracellular
proteins through a mechanism known as antigen presentation. The mechanism exists to detect
the presence of non-self, pathogen-derived proteins in compromised cells, but works in favor of
cancer therapy as T-cells would consider mutated proteins to be non-self.
1.4 Antigen presentation, MHC, and the T-cell response
The MHC- or HLA-type (Human Leukocyte Antigen) of a person is a representation of the set of
MHC molecules encoded within the genome of the person. Naturally occurring variations in the
MHC arise from polygeny (multiple MHC genes of the same class) and polymorphism (multiple
types of the same MHC molecule). Through a combination of the two, humans have a total of
6 peptide-displaying MHC class I proteins encoded in their genome (1 each of HLA-A, HLA-
B and HLA-C on each chromosome). The number of assembled peptide-displaying MHCII
complexes can be larger as each HLA-DP, DQ and DR molecule depends on a combination of α
and β sub-molecules in their respective loci. MHC molecules of different types differ in the type
of peptide that they bind to [56, 78], hence heterozygosity (having different alleles) increases
the potential number of peptides displayed on the cell surface, and the immune system’s power
in detecting a new non-self protein.
The short peptides produced during recycling of cellular proteins are transported into
the endoplasmic reticulum (ER) of the cell via TAP transport proteins. The peptides are further
processed within the ER before being loaded onto MHCI molecules and transported to the cell
surface for display. The final displayed peptide is roughly 8-10 amino acids in length [56, 78].
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Figure 1.2: Schematic representation of the methods of antigen presentation in cells. a) In-
tracellular proteins are processed via the MHCI pathway and are displayed to CD8+ cells. b)
Extracellular antigens are endocytosed and processed via the MHCII pathway in APCs before
being displayed to CD4+ cells. c) Dendritic cells can also “cross-present” extracellular antigens
via the MHCI pathway. Figure obtained from Heath and Carbone, Nature Reviews Immunology
[45].
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Figure 1.2a gives a schematic of the MHCI processing pathway. CD8+ Cytotoxic T-Cells of
the immune system can recognize MHCI displayed peptides and are programmed to destroy the
cell if they sense that the peptide is derived from a non-self protein.
Class II MHC molecules are primarily produced by phagocytic cells. Cells that consti-
tutively express both MHC I and II are known as Professional Antigen Presenting Cells(APCs).
These include dendritic cells, macrophages, and some B cells. The role of MHCII in the im-
mune response is the activation or “priming” of CD4+ cells. MHCII displayed proteins are
derived from extracellular protein endocytosed into the cell, or from dendritic cells “nibbling”
on live cells [44]. The endocytosed material could be either secreted cell protein, small mi-
croorganisms, or cell proteins released into the cellular matrix after cell membrane rupture.
The endocytosed protein is subjected to acid hydrolysis in endocytic vesicles and loaded onto
MHCII molecules that are pre-assembled in the endoplasmic reticulum [56, 78]. Figure 1.2b
shows the MHCII processing pathway of extracellular protein. CD4+ cells detect MHCII dis-
played peptide and, given the right co-stimulation, can induce enhanced activity of the adaptive
immune response.
Dendritic cells, in particular, also have a unique function known as cross presentation.
In cross presentation, cells uptake extracellular pathogenic material via endocytosis and process
it via the MHCI pathway instead of the MHCII pathway. In this manner, dendritic cells can
prime CD8+ cells for specificity to the antigen, without getting infected themselves (Figure
1.2c) [45].
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1.5 Cancer Immunoediting
Cancers are frequently associated with a high degree of chromosomal instability and subse-
quently, a high mutational burden. The logical question to ask is, “If cancers have a high rate
of mutation and produce peptides foreign to the body, why doesn’t the immune system detect
and destroy tumor cells?” The short answer is that the immune system can, and does mount a
response to the tumor. However, tumors have ways to evade the immune system.
The tumoral response to the immune system is often referred to as the ‘Three E’s of
cancer immunoediting’, Elimination, Equilibrium, and Escape [30, 29, 62]. This idea suggests
that in the early stage of tumor development, the innate and adaptive immune system react to
the cancer and eliminate the cells in the growing tumor. Eventually, the cells within the tumor
that do not harbor the mutations detected by the immune system gain a selective advantage and
begin to grow in number. In this equilibrium state, the immune system continues to kill the cells
it can target while other tumor cells slowly rise in number. At a certain point, the tumor develops
enough cells to overcome the immune response and this leads to immune escape. Figure 1.3
shows the stages of Immunoediting in a cartoon form.
1.6 Cancer immunotherapy
Cancer immunotherapy involves using the immune system to treat cancers. There are 4 well
defined cancer immunotherapy techniques: antibody based therapies, Checkpoint Blockade,
Adoptive Cell Therapies (ACTs), and Vaccine-based Therapies. Each of these therapies directly
10
Figure 1.3: The Three E’s of Immunoediting; Elimination, Equilibrium, and Escape. Figure
obtained from Dunn et.al., Nature Reviews Immunology [29].
or indirectly uses elements of the patient’s immune system to selectively attack the tumor.
1.6.1 Antibody-based therapies
Antibody based therapies take advantage of the high specificity of antibodies to their targets, and
are used to selectively attack tumor cells that have unique cancer-specific cell-surface proteins.
Antibody binding to the cell-surface proteins can lead to cell death via Antibody Dependent
Cell-mediated Cytotoxicity (ADCC) or complement. In ADCC, immune cells (primarily of the
NK lineage) bind to the Fc regions of antigen bound antibody and destroy the cell harboring the
antigen. Complement involves the formation of a membrane attack complex via the alternate
pathway of complement activation. Antibodies can also be used to deliver drugs selectively
to the tumor cells [103, 116]. Antibody based methods (B-cell methods) are effective only if
the tumor has a mutation in a cell-surface protein. The method does not consider the entire
landscape of the tumoral DNA.
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1.6.2 Checkpoint Blockade
Checkpoint Blockade is also an antibody mediated method, however instead of targeting the
tumor cell for destruction, it prevents immune suppression via targeted blockade of specific
immune signaling molecules [13, 104]. The immune system has safeguards in place to stop an
immune reaction after a threat has been neutralized. These safeguards are often exploited by the
tumor to escape the immune response [80, 38, 37, 55]. Targeting key molecules in the immune
regulatory pathway such as Programmed Cell Death Receptor Protein 1 (PD-1), Programmed
Death-Ligand 1 (PD-L1), and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) have
been shown to improve antitumor immunity [108, 29, 25, 72, 53, 49, 50]. Targeting immune
regulatory checkpoint molecules can however lead to autoimmune reactions [24, 31] and should
not be administered over a long period of time. More recent practices include targeting multiple
checkpoint molecules simultaneously, and combining checkpoint blockade with Adoptive Cell
Therapies for increased effect.
1.6.3 Adoptive cell therapy
Adoptive cell therapies for cancer use autologously derived T-cells to treat a patient. The T-cells
can either be cells isolated from the patient and assayed for tumor specificity, or T-cells from
the patient that are genetically engineered to produce T-cell receptors (TCRs) specific for the
patient’s MHC restriction. Genetically modified TCRs can be obtained from transgenic mice or
from human cells [92].
In traditional Adoptive T-cell therapy, the TCR repertoire naturally within the patient
12
is assayed for tumor specificity. Intravital imaging studies showed that T cell migration rapidly
arrests when they encounter APCs in the tumor displaying their cognate antigen [26]. These T-
cells are known as Tumor Infiltrating Lymphocytes (TILs). Early methods for priming patient T
cells used autologous tumor and normal cells to test for reactivity in TILs [79, 92]. This method
showed promise in a subgroup of patients diagnosed with melanoma [94]. In a cohort of 93
patients, 20 showed complete regression of the tumor with 3- and 5-year survival rates of 100%
and 93% respectively; 32 patients showed partial response and had survival rates of 31% and
21%, while the 42 non-responders had 7% and 5% 3- and 5-year survival rates respectively. 19
of the complete responders showed ongoing complete regression 37 to 82 months after the first
treatment. While the complete responders show great potential for the method, a 21.5% success
rate is still not an ideal solution.
Not all TILs have the potential to attack tumor cells in vivo. Some TILs are rendered
anergic due to a lack of co-stimulation after recognizing their cognate antigen, a fail-safe mech-
anism used by the immune system to prevent autoimmunity. TILs can also be repressed due to
immunomodulatory action of the tumor [12]. Updated TIL based methods involve extracting
TILs from the tumor followed by in-vitro stimulation using dendritic cells [113]. Mutations in
the tumor are identified using computational methods and short contiguous stretches of DNA
encoding the variant-containing regions are synthesized (“Tandem Minigenes”) are transfected
into dendritic cells. The dendritic cells translate the minigenes and process them to produce the
epitopes predicted to be seen on the tumor surfaces. The dendritic cells can be used to stimulate
tumor-responsive CTLs, which can be grown in-vitro before being re-infused into the patient.
Figure 1.4 describes the adoptive T-cell therapy methodology.
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Figure 1.4: Schematic representation of adoptive T-cell therapy. Mutations in coding regions
of the tumor DNA can be scanned for potential aberrant protein products and used to activate
autologous T-cells. Figure obtained from Restifo et.al., Nature Reviews Immunology [93].
In cases where there is no evidence of the patient having already mounted an immune
response to the tumor, engineered T-cells can be used to attack the tumor cells. Two common
methods of genetically engineering T-cells are Chimeric Antigen Receptor (CAR) engineering,
and TCR transformation. In CAR therapies, autologous T-Cells from the patient are extracted
and engineered to express a Chimeric Antigen Receptor, a receptor that is a chimera between
the antigen-recognition domains of an antibody and the ζchain of a TCR along with some co-
stimulatory domains like CD28 and 4-1BB [32, 61, 52, 96, 88]. The recognition domains are
targeted against cell-surface molecules on the tumor and antigen recognition stimulates IL2
production and an immune response. This method is highly work intensive, but has proved to
be very effective in its action [70, 9, 84]. For example, CD-19 is a cell-surface marker present
only in B-Cell lineages, making it a prime target for treatment of acute lymphoblastic leukemia
(ALL), chronic lymphoblastic leukemia (CLL), and some forms of Hodgkin’s lymphoma. In
14
2011, Kalos et.al. showed that anti-CD19 CAR T-cells against patients with advanced leukemia
showed tumor reduction and even memory potential despite being engineered [57]. The draw-
back of CAR-T methods is that CARs can only recognize cell-surface proteins and very few
tumors produce unique molecules that are absent on any other normal cell type. TCR transfor-
mation therapies involve identification of cells reactive to tumor antigen and transformation of
the TCR genes from that cell into patient T-cells using retroviral or lentiviral vectors [54, 92].
The TCRs transformed into the patient need to be extracted from cells having the same MHC
restriction as the patient for the therapy to work. TCRs can be obtained from cell lines, cells
taken from other patients with the same MHC restriction, or humanized mice engineered to
produce human MHCI molecules. Figure 1.5 describes how engineered T-cells can be used in
therapy.
Figure 1.5: Schematic representation of Engineered T-cells used in adoptive T-cell therapy. T-
cells can be engineered with Chimeric Antigen Receptors(CARs) or T-cell Receptors grown
in-vitro to enhance the immune reaction. Figure obtained from Restifo et.al., Nature Reviews
Immunology [93].
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1.6.4 Vaccine-based therapies
Vaccine therapies are the most recent generation of cancer immunotherapy. These methods
include vaccination of a patient with synthetic peptides [85] or neoepitope-encoding RNA [97]
using a suitable vector. Dendritic cells in the skin uptake the vaccine molecules and process
them into cell-surface MHCI/II displayed neoepitopes. CD8+ stimulated by these dendritic
cells are then capable of selectively targeting the tumor, while CD4+ cells can recruit other cells
of the immune system.
Figure 1.6: Schematic representation of a peptide vaccine workflow for cancer therapy. Figure
obtained from Sahin and Tu¨reci, Science [98].
1.7 Thesis statement
Identification of peptides displayed on a tumor’s cell surface MHCs, and which ones will elicit a
response, is currently a time- and labor intensive process due to lack of good prediction models.
Patients diagnosed with cancers - especially cancers with poor prognoses such as glioblastomas
- are in a race against time and need fast and accurate treatments. TIL- and Vaccine-based
methods are limited by the number of minigenes synthesized and tested before arriving at a
16
therapeutic target. This thesis describes a workflow to automate the identification of ranked
neoepitope targets in a patient that can be used to restrict the search space for a TIL-based or
Vaccine-based immune therapy.
17
Chapter 2
Efficient workflow scheduling using Toil
2.1 Introduction
The genomics industry has seen huge growth in the past decade. The amount of sequencing
data available on the internet has increased greatly with the advent of better, high throughput
technologies. For example. the Sequence Read Archive (SRA) [67] at the National Center for
Biotechnology Information (NCBI) has grown from 20.3 total Gigabases (Gb) in June 2007 to
16.7 Petabases (Pb) in May 2018.
Bioinformatics pipelines are often associated with high I/O tasks due to the large file-
sizes of FASTQs, BAMs, etc. Toil caches the results from jobs such that child jobs running
on the same node in a distributed cluster can directly use the same file objects, thereby elimi-
nating the need for an intermediary transfer to the job store. Multiple jobs one the same node
requesting the same immutable file from the jobstore share the same file object deposited in the
cache, reducing the burden on the disk. This resulting drop in I/O allows pipelines to run faster,
18
and, by the sharing of files, allows users to run more jobs in parallel by reducing overall disk
requirements.
My contribution to the Toil project included the implementation of caching to the file
store along with numerous unit tests to ensure all the code works perfectly, and the detailed
documentation for the manual (submitted as the supplementary for the paper). I made other
small contributions to the software during my time working on the project. Toil was published
as a proof-of-concept paper in Nature Biotechnology in April 2017 and is included in the next
section. I helped write and edit all versions of the manuscript before publication. The relevant
section of the supplementary with my contribution has been provided below and Figure 7.1
shows my contribution to the project was substantial from the time I started to the time of
publication.
I want to acknowledge the contributions of John Vivian, the lead author of the paper
who developed and ran the RNA-Seq analysis used to demonstrate Toil in the paper. I also want
to Acknowledge Hannes Schmidt, the computational lead on the software whose brutal code
reviews made me an infinitely better programmer.
2.2 The Toil paper
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open sharing of protocols. With a precise 
ontology to describe standardized protocols, 
it may be possible to share methods widely 
and create community standards.
We envisage that in future individual 
research laboratories, or clusters of co-
located laboratories, will have in-house, 
low-cost automation work cells but will 
access DNA foundries via the cloud to 
carry out complex experimental workflows. 
Technologies enabling this from companies 
such as Emerald Cloud Lab (S. San 
Francisco, CA, USA), Synthace (London) 
and Transcriptic (Menlo Park, CA, USA) 
could, for example, send experimental 
designs to foundries and return output 
data to a researcher. This ‘mixed economy’ 
should accelerate the development and 
sharing of standardized protocols and 
metrology standards and shift a growing 
proportion of molecular, cellular and 
synthetic biology into a fully quantitative 
and reproducible era.
To the Editor:
Contemporary genomic data sets contain 
tens of thousands of samples and petabytes 
of sequencing data1–3. Pipelines to process 
genomic data sets often comprise dozens 
of individual steps, each with their own set 
of parameters4,5. Processing data at this 
scale and complexity is expensive, can take 
an unacceptably long time, and requires 
significant engineering effort. Furthermore, 
biomedical data sets are often siloed, both for 
organizational and security considerations 
and because they are physically difficult 
to transfer between systems, owing to 
bandwidth limitations. The solution to better 
handling these big data problems is twofold: 
first, we need robust software capable of 
running analyses quickly and efficiently, and 
second, we need the software and pipelines to 
be portable, so that they can be reproduced in 
any suitable compute environment.
Here, we present Toil, a portable, open-
source workflow software that can be used 
to run scientific workflows on a large scale 
in cloud or high-performance computing 
(HPC) environments. Toil was created to 
include a complete set of features necessary 
for rapid large-scale analyses across multiple 
environments. While several other scientific 
workflow software packages6–8 offer some 
subset of fault tolerance, cloud support and 
HPC support, none offers these with the 
scale and efficiency to process petabyte and 
larger-scale data sets efficiently. This sets Toil 
apart in its capacity to produce results faster 
and for less cost across diverse environments. 
We demonstrate Toil by processing >20,000 
RNA-seq samples (Fig. 1). The resulting 
meta-analysis of five data sets is available 
to readers9. The large majority (99%) of 
these samples were analyzed in under 4 days 
using a commercial cloud cluster of 32,000 
preemptable cores.
To support the sharing of scientific 
workflows, we designed Toil to execute 
common workflow language (CWL; 
Supplementary Note 1) and provide draft 
support for workflow description language 
(WDL). Both CWL and WDL are standards 
for scientific workflows10,11. A workflow 
comprises a set of tasks, or ‘jobs’, that are 
orchestrated by specification of a set of 
dependencies that map the inputs and 
outputs between jobs. In addition to CWL 
and draft WDL support, Toil provides a 
Python application program interface (API) 
that allows workflows to be declared statically, 
or generated dynamically, so that jobs can 
define further jobs during execution and 
therefore as needed (Supplementary Note 2 
and Supplementary Toil Documentation). 
The jobs defined in either CWL or Python 
can consist of Docker containers, which 
permit sharing of a program without 
requiring individual tool installation or 
configuration within a specific environment. 
Open-source workflows that use containers 
can be run regardless of environment. We 
provide a repository of genomic workflows 
as examples12. Toil supports services, such 
as databases or servers, that are defined and 
Figure 1  RNA-seq pipeline and expression concordance. (a) A dependency graph of the RNA-seq 
pipeline we developed (named CGL). CutAdapt was used to remove extraneous adapters, STAR was 
used for alignment and read coverage, and RSEM and Kallisto were used to produce quantification 
data. (b) Scatter plot showing the Pearson correlation between the results of the TCGA best-practices 
pipeline and the CGL pipeline. 10,000 randomly selected sample and/or gene pairs were subset from 
the entire TCGA cohort and the normalized counts were plot against each other; this process was 
repeated five times with no change in Pearson correlation. The unit for counts is: log2(norm_counts+1).
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protection of the input data, and as part 
of a broader security plan, can be used to 
ensure compliance with strict data security 
requirements.
To demonstrate Toil, we used a single 
script to compute gene- and isoform-level 
expression values for 19,952 samples from 
four studies: The Cancer Genome Atlas 
(TCGA)1, Therapeutically Applicable 
Research To Generate Effective Treatments 
(TARGET; https://ocg.cancer.gov/programs/
target), Pacific Pediatric Neuro-Oncology 
Consortium (PNOC; http://www.pnoc.
us/), and the Genotype Tissue Expression 
Project (GTEx)18. The data set comprised 108 
terabytes. The Toil pipeline uses STAR19 to 
generate alignments and read coverage graphs, 
and performs quantification using RSEM20 
and Kallisto21 (Fig. 1 and Supplementary 
Note 6). Processing the samples in a single 
batch on ~32,000 cores on AWS took 90 h of 
wall time, 368,000 jobs and 1,325,936 core 
hours. The cost per sample was $1.30, which 
is an estimated 30-fold reduction in cost, and 
a similar reduction in time, compared with 
the TCGA best-practices workflow5. We 
achieved a 98% gene-level concordance with 
the previous pipeline’s expression predictions 
(Figs. 1,2 and Supplementary Fig. 1). 
Notably, we estimate that the pipeline, without 
STAR and RSEM, could be used to generate 
quantifications for $0.19/sample with Kallisto. 
To illustrate portability, the same pipeline was 
run on the I-SPY2 data set22 (156 samples) 
using a private HPC cluster, achieving similar 
per sample performance (Supplementary 
Table 1). Expression-level signal graphs (read 
coverage) of the GTEx data (7,304 samples 
from 53 tissues, 570 donors) are available from 
a UCSC Genome Browser23 public track hub 
(Supplementary Fig. 2). Gene and isoform 
quantifications for this consistent, union data 
set are publicly hosted on UCSC Xena9 and 
are available for direct access through a public 
AWS bucket (Supplementary Fig. 3 and 
Supplementary Note 7).
Although there is an extensive history of 
open-source workflow-execution software6–8, 
the shift to cloud platforms and the advent of 
standard workflow languages is changing the 
scale of analyses. Toil is a portable workflow 
software that supports open community 
standards for workflow specification and 
enables researchers to move their computation 
according to cost, time and data location. For 
example, in our analysis the sample data were 
intentionally co-located in the same region 
as the compute servers in order to provide 
optimal bandwidth when scaling to thousands 
of simultaneous jobs (Supplementary Note 
8). This type of flexibility enables larger, more 
managed within a workflow. Through this 
mechanism it integrates with Apache Spark13 
(Supplementary Fig. 4), and can be used to 
rapidly create containerized Spark clusters14 
(Supplementary Note 3).
Toil runs in multiple cloud environments 
including those of Amazon Web Services 
(AWS; Seattle, WA, USA), Microsoft Azure 
(Seattle, WA, USA), Google Cloud (Mountain 
View, CA, USA), OpenStack, and in HPC 
environments running GridEngine or Slurm 
and distributed systems running Apache 
Mesos15–17 (Forest Hill, MD, USA). Toil can 
run on a single machine, such as a laptop 
or workstation, to allow for interactive 
development, and can be installed with a 
single command. This portability stems 
from pluggable backend APIs for machine 
provisioning, job scheduling and file 
management (Supplementary Note 4). 
Implementation of these APIs facilitates 
straightforward extension of Toil to new 
compute environments. Toil manages 
intermediate files and checkpointing through 
a ‘job store’, which can be an object store 
like AWS’s S3 or a network file-system. The 
flexibility of the backend APIs allow a single 
script to be run on any supported compute 
environment, paired with any job store, 
without requiring any modifications to the 
source code.
Toil includes numerous performance 
optimizations to maximize time and cost 
efficiencies (Supplementary Note 5). Toil 
implements a leader/worker pattern for job 
scheduling, in which the leader delegates jobs 
to workers. To reduce pressure on the leader, 
workers can decide whether they are capable 
of running jobs immediately downstream 
to their assigned task (in terms of resource 
requirements and workflow dependencies). 
Frequently, next-generation sequencing 
workflows are I/O bound, owing to the large 
volume of data analyzed. To mitigate this, Toil 
uses file caching and data streaming. Where 
possible, successive jobs that share files are 
scheduled on a single node, and caching 
prevents the need for repeated transfers from 
the job store. Toil is robust to job failure 
because workflows can be resumed after any 
combination of leader and worker failures. 
This robustness enables workflows to use 
low-cost machines that can be terminated by 
the provider at short notice and are currently 
available at a significant discount on AWS and 
Google Cloud. We estimate the use of such 
preemptable machines on AWS lowered the 
cost of our RNA-seq compute job 2.5-fold, 
despite encountering over 2,000 premature 
terminations (Fig. 2). Toil also supports 
fine-grained resource requirements, enabling 
each job to specify its core, memory and local 
storage needs for scheduling efficiency.
Controlled-access data requires appropriate 
precautions to ensure data privacy and 
protection. Cloud environments offer 
measures that ensure stringent standards for 
protected data. Input files can be securely 
stored on object stores, using encryption, 
either transparently or with customer 
managed keys. Compute nodes can be 
protected by SSH key pairs. When running 
Toil, all intermediate data transferred to 
and from the job store can be optionally 
encrypted during network transmission and 
on the compute nodes’ drives using Toil’s 
cloud-based job store encryption. These 
and other security measures help ensure 
Figure 2  Costs and core usage. (a) Scaling tests were run to ascertain the price per sample at varying 
cluster sizes for the different analysis methods. TCGA (red) shows the cost of running the TCGA best-
practices pipeline as re-implemented as a Toil workflow (for comparison). CGL-One-Sample/Node (cyan) 
shows the cost of running the revised Toil pipeline, one sample per node. CGL (blue) denotes the pipeline 
running samples across many nodes. CGL-Spot (green) is the same as CGL, but denotes the pipeline run 
on the Amazon spot market. The slight rise in cost per sample at 32,000 cores was due to a couple of 
factors: aggressive instance provisioning directly affected the spot price (dotted line), and saving bam and 
bedGraph files for each sample. (b) Tracking number of cores during the recompute. The two red circles 
indicate where all worker nodes were terminated and subsequently restarted shortly thereafter.
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comprehensive analyses. Further, it means that 
results can be reproduced using the original 
computation’s set of tools and parameters. If 
we had run the original TCGA best-practices 
RNA-seq pipeline with one sample per node, 
it would have cost ~$800,000. Through the 
use of efficient algorithms (STAR and Kallisto) 
and Toil, we were able to reduce the final cost 
to $26,071 (Supplementary Note 9).
We have demonstrated the utility of Toil by 
creating one of the single largest, consistently 
analyzed, public human RNA-seq expression 
repositories, which we hope the community 
will find useful.
Editor’s note: This article has been peer-reviewed.
Note: Any Supplementary Information and Source Data 
files are available in the online version of the paper.
ACKNOWLEDGMENTS
This work was supported by (BD2K) the National 
Human Genome Research Institute of the National 
Institutes of Health award no. 5U54HG007990 and 
(Cloud Pilot) the National Cancer Institute of the 
National Institutes of Health under the Broad Institute 
subaward no. 5417071-5500000716. The UCSC 
Genome Browser work was supported by the NHGRI 
award 5U41HG002371 (Corporate Sponsors). The 
content is solely the responsibility of the authors and 
does not necessarily represent the official views of 
the National Institutes of Health or our corporate 
sponsors.
AUTHOR CONTRIBUTIONS
J.V., A.A.R. and B.P wrote the manuscript. J.V., A.A.R., 
A.N., J.A., C.K., J.N., H.S., P.A., J.P., A.D.D., B.O. and 
B.P. contributed to Toil development. F.A.N. and A.M. 
contributed to Toil-Spark integration. J.V. wrote the 
RNA-seq pipeline and automation software. M.H. 
and C.B. contributed WDL and cloud support. P.A. 
and S.Z. contributed CWL support. J.Z., B.C. and 
M.G. hosted quantification results on UCSC Xena. 
K.R. hosted GTEx results in UCSC Genome Browser. 
W.J.K., J.Z., S.Z., G.G., D.A.P., A.D.J., M.C., D.H. 
and B.P. provided scientific leadership and project 
oversight.
Data availability. Data are available from this project 
at the Toil xena hub (https://genome-cancer.soe.
ucsc.edu/proj/site/xena/datapages/?host=https://toil.
xenahubs.net).
COMPETING FINANCIAL INTERESTS
The authors declare competing financial interests: 
details are available in the online version of the paper.
John Vivian1, Arjun Arkal Rao1,  
Frank Austin Nothaft2,3, Christopher Ketchum1, 
Joel Armstrong1, Adam Novak1, Jacob Pfeil1, 
Jake Narkizian1, Alden D Deran1,  
Audrey Musselman-Brown1, Hannes Schmidt1, 
Peter Amstutz4, Brian Craft1, Mary Goldman1,  
Kate Rosenbloom1, Melissa Cline1,  
Brian O’Connor1, Megan Hanna5, Chet Birger5, 
W James Kent1, David A Patterson2,3,  
Anthony D Joseph2,3, Jingchun Zhu1,  
Sasha Zaranek4, Gad Getz5, David Haussler1 & 
Benedict Paten1
1Computational Genomics Lab, UC Santa Cruz 
Genomics Institute, University of California 
10. Amstutz, P. Common workflow language. Github 
https://github.com/common-workflow-language/com-
mon-workflow-language (2016).
11. Frazer, S. Workflow description language. Github 
https://github.com/broadinstitute/wdl (2014).
12. Vivian, J. Toil scripts. Github https://github.com/
BD2KGenomics/toil-scripts/tree/master/src/toil_
scripts (2016).
13. Apache Software Foundation. Apache Spark http://
spark.apache.org/ (2017).
14. Massie, M. et al. ADAM: genomics formats and pro-
cessing patterns for cloud scale computing. University 
of California, Berkeley, Technical Report No. UCB/
EECS-2013-207 (2013).
15. Gentzsch, W. in Proceedings First IEEE/ACM 
International Symposium on Cluster Computing 
and the Grid 35–36 http://dx.doi.org/10.1109/
ccgrid.2001.923173 (IEEE, 2001).
16. Yoo, A.B., Jette, M.A. & Mark, G. in Lecture Notes in 
Computer Science 44–60 (2003) Springer, Berlin, 
Heidelberg.
17. Apache Software Foundation. Apache Mesos http://
mesos.apache.org/
18. GTEx Consortium. Science 348, 648–660 (2015). 
19. Dobin, A. et al. Bioinformatics 29, 15–21 (2013). 
20. Li, B. & Dewey, C.N. BMC Bioinformatics 12, 323 
(2011). 
21. Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. 
Nat. Biotechnol. 34, 525–527 (2016).
22. Barker, A.D. et al. Clin. Pharmacol. Ther. 86, 97–100 
(2009). 
23. Kent, W.J. et al. Genome Res. 12, 996–1006 
(2002). 
To the Editor:
The increasing complexity of readouts for 
omics analyses goes hand-in-hand with 
concerns about the reproducibility of 
experiments that analyze ‘big data’1–3. When 
analyzing very large data sets, the main source 
of computational irreproducibility arises from 
a lack of good practice pertaining to software 
and database usage4–6. Small variations across 
computational platforms also contribute to 
computational irreproducibility by producing 
numerical instability7, which is especially 
relevant to high-performance computational 
(HPC) environments that are routinely used 
for omics analyses8. We present a solution to 
this instability named Nextflow, a workflow 
management system that uses Docker 
technology for the multi-scale handling of 
containerized computation.
In silico workflow management systems 
are an integral part of large-scale biological 
analyses. These systems enable the rapid 
prototyping and deployment of pipelines that 
combine complementary software packages. 
In genomics the simplest pipelines, such as 
Kallisto and Sleuth9, combine an RNA-seq 
quantification method with a differential 
expression module (Supplementary Fig. 1). 
Complexity rapidly increases when all aspects 
of a given analysis are included. For example, 
the Sanger Companion pipeline10 bundles 
39 independent software tools and libraries 
into a genome annotation suite. Handling 
such a large number of software packages, 
some of which may be incompatible, is a 
challenge. The conflicting requirements of 
frequent software updates and maintaining 
the reproducibility of original results provide 
another unwelcome wrinkle. Together with 
these problems, high-throughput usage of 
complex pipelines can also be burdened by the 
hundreds of intermediate files often produced 
by individual tools. Hardware fluctuations in 
these types of pipelines, combined with poor 
error handling, could result in considerable 
readout instability.
Nextflow (http://nextflow.io; 
Supplementary Methods, Supplementary 
Note and Supplementary Code 1) is 
designed to address numerical instability, 
efficient parallel execution, error tolerance, 
execution provenance and traceability. It is a 
domain-specific language that enables rapid 
pipeline development through the adaptation 
of existing pipelines written in any scripting 
language.
We present a qualitative comparison 
between Nextflow and other similar tools in 
Table 1 (ref. 11). We found that multi-scale 
containerization, which makes it possible to 
Nextflow enables reproducible 
computational workflows
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2.3 The Toil paper supplementary
The entire supplementary pdf contains details regarding the RNA-Seq pipeline, Spark support,
CWL support, etc, and contains the entire Toil manual for version 3.2.0a2 (including docu-
mentation for every API call in the package). Since most of this data is irrelevant to this
thesis, only the relevant pages are provided below. The full supplementary pdf can be ob-
tained from https://media.nature.com/original/nature-assets/nbt/journal/v35/
n4/extref/nbt.3772-S1.pdf
2.3.1 Supplementary Toil documentation, chapter 8
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CHAPTER
EIGHT
TOIL ARCHITECTURE
The following diagram layouts out the software architecture of Toil.
Fig. 8.1: Figure 1: The basic components of the toil architecture. Note the node provisioning is coming soon.
These components are described below:
• the leader: The leader is responsible for deciding which jobs should be run. To do this it traverses the job
graph. Currently this is a single threaded process, but we make aggressive steps to prevent it becoming
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a bottleneck (see Read-only Leader described below).
• the job-store: Handles all files shared between the components. Files in the job-store are the means by
which the state of the workflow is maintained. Each job is backed by a file in the job store, and atomic
updates to this state are used to ensure the workflow can always be resumed upon failure. The job-
store can also store all user files, allowing them to be shared between jobs. The job-store is defined
by the abstract class toil.jobStores.AbstractJobStore. Multiple implementations of this
class allow Toil to support different back-end file stores, e.g.: S3, network file systems, Azure file
store, etc.
• workers: The workers are temporary processes responsible for running jobs, one at a time per worker.
Each worker process is invoked with a job argument that it is responsible for running. The worker
monitors this job and reports back success or failure to the leader by editing the job’s state in the
file-store. If the job defines successor jobs the worker may choose to immediately run them (see Job
Chaining below).
• the batch-system: Responsible for scheduling the jobs given to it by the leader, creating a
worker command for each job. The batch-system is defined by the abstract class class
toil.batchSystems.AbstractBatchSystem. Toil uses multiple existing batch systems to
schedule jobs, including Apache Mesos, GridEngine and a multi-process single node implementation
that allows workflows to be run without any of these frameworks. Toil can therefore fairly easily be
made to run a workflow using an existing cluster.
• the node provisioner: Creates worker nodes in which the batch system schedules work-
ers. This is currently being developed. It is defined by the abstract class
toil.provisioners.AbstractProvisioner.
• the statistics and logging monitor: Monitors logging and statistics produced by the workers and reports
them. Uses the job-store to gather this information.
8.1 Optimizations
Toil implements lots of optimizations designed for scalability. Here we detail some of the key optimizations.
8.1.1 Read-only leader
The leader process is currently implemented as a single thread. Most of the leader’s tasks revolve around processing
the state of jobs, each stored as a file within the job-store. To minimise the load on this thread, each worker does as
much work as possible to manage the state of the job it is running. As a result, with a couple of minor exceptions,
the leader process never needs to write or update the state of a job within the job-store. For example, when a job is
complete and has no further successors the responsible worker deletes the job from the job-store, marking it complete.
The leader then only has to check for the existence of the file when it receives a signal from the batch-system to know
that the job is complete. This off-loading of state management is orthogonal to future parallelization of the leader.
8.1.2 Job chaining
The scheduling of successor jobs is partially managed by the worker, reducing the number of individual jobs the leader
needs to process. Currently this is very simple: if the there is a single next successor job to run and it’s resources fit
within the resources of the current job and closely match the resources of the current job then the job is run immediately
on the worker without returning to the leader. Further extensions of this strategy are possible, but for many workflows
which define a series of serial successors (e.g. map sequencing reads, post-process mapped reads, etc.) this pattern is
very effective at reducing leader workload.
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8.1.3 Preemptable node support
Critical to running at large-scale is dealing with intermittent node failures. Toil is therefore designed to always be
resumable providing the job-store does not become corrupt. This robustness allows Toil to run on preemptible nodes,
which are only available when others are not willing to pay more to use them. Designing workflows that divide
into many short individual jobs that can use preemptable nodes allows for workflows to be efficiently scheduled and
executed.
8.1.4 Caching
Running bioinformatic pipelines often require the passing of large datasets between jobs. Toil caches the results from
jobs such that child jobs running on the same node can directly use the same file objects, thereby eliminating the need
for an intermediary transfer to the job store. Caching also reduces the burden on the local disks, because multiple jobs
can share a single file. The resulting drop in I/O allows pipelines to run faster, and, by the sharing of files, allows users
to run more jobs in parallel by reducing overall disk requirements.
To demonstrate the efficiency of caching, we ran an experimental internal pipeline on 3 samples from the TCGA
Lung Squamous Carcinoma (LUSC) dataset. The pipeline takes the tumor and normal exome fastqs, and the tu-
mor rna fastq and input, and predicts MHC presented neoepitopes in the patient that are potential targets for T-cell
based immunotherapies. The pipeline was run individually on the samples on c3.8xlarge machines on AWS (60GB
RAM,600GB SSD storage, 32 cores). The pipeline aligns the data to hg19-based references, predicts MHC haplotypes
using PHLAT, calls mutations using 2 callers (MuTect and RADIA) and annotates them using SnpEff, then predicts
MHC:peptide binding using the IEDB suite of tools before running an in-house rank boosting algorithm on the final
calls.
To optimize time taken, The pipeline is written such that mutations are called on a per-chromosome basis from the
whole-exome bams and are merged into a complete vcf. Running mutect in parallel on whole exome bams requires
each mutect job to download the complete Tumor and Normal Bams to their working directories – An operation that
quickly fills the disk and limits the parallelizability of jobs. The script was run in Toil, with and without caching, and
Figure 2 shows that the workflow finishes faster in the cached case while using less disk on average than the uncached
run. We believe that benefits of caching arising from file transfers will be much higher on magnetic disk-based storage
systems as compared to the SSD systems we tested this on.
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Fig. 8.2: Figure 2: Efficiency gain from caching. The lower half of each plot describes the disk used by the pipeline
recorded every 10 minutes over the duration of the pipeline, and the upper half shows the corresponding stage of the
pipeline that is being processed. Since jobs requesting the same file shared the same inode, the effective load on the
disk is considerably lower than in the uncached case where every job downloads a personal copy of every file it needs.
We see that in all cases, the uncached run uses almost 300-400GB more that the uncached run in the resource heavy
mutation calling step. We also see a benefit in terms of wall time for each stage since we eliminate the time taken for
file transfers.
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Chapter 3
Translation of genomic mutations into
therapeutically assayable peptides
3.1 Introduction
In order to predict tumor neoepitopes of clinical significance, we need a reliable tool to trans-
late the mutations from genomic space into peptides that can be assayed with existing pep-
tide:MHC (pMHC) binding affinity predictors. Variant annotators like SNPEff [19], VEP [75]
and TransVar [122] can annotate individual single nucleotide variants(SNVs), and short in-
sertions and deletions (INDELs), providing details on the exact change in the amino acid se-
quences. Fusion genes (Fusions) are identified from the genomic breakpoints and are usually
annotated by the Fusion caller. To predict neoepitopes of length n using an existing pMHC
binding affinity predictor, we need at least n− 1 amino acids flanking the variant. Since no
freely available tool exists to predict mutated peptides, I developed TransGene.
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TransGene is a standalone python tool capable of processing any combination of
SNVs, INDELs, and Fusion Genes to variant-containing predict peptides from the tumor pro-
teome. TransGene can use provided RNA-Seq data to confidently predict only peptides arising
from transcribed variants, and DNA-Seq to filter reads arising from Oxidation of Guanosine
(OxoG) [23] events. TransGene can also phase and merge events within a short distance of each
other if they can potentially fit on the same neoepitope. The variant containing peptides pro-
duced by TransGene are called ImmunoActive Regions (IARs) as they can potentially stimulate
the immune system.
With the exception of a few auxiliary modules used in fusion gene handling, I de-
veloped every module in the TransGene package. This includes the modules to process calls
from every version of SNPEff, process VEP calls, use RNA-Seq to filter variants with low allele
frequency, use DNA-Seq to filter OxoG events, and the modules to predict IARs from SNVs,
INDELs and Fusions. The first pass at handling fusion genes was written by Jacob Pfeil un-
der my guidance. Since then, I have added code to filter artifacts arising from the fusion gene
prediction process and completely rewrote the way IARs are predicted from breakpoints.
I ran TransGene on the input dataset, analyzed and documented the results, and wrote
the entire paper with edits from Dr. Sofie Salama and Dr. David Haussler. The text and
supplementary for the proposed paper are provided below.
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3.2 The TransGene paper
3.2.1 Abstract
Somatic mutations in cancer cells can produce peptides recognized by autologous T-cells as
non-self, resulting in an immune reaction to the tumor. We developed TransGene to translate
somatic mutants identified by DNA sequence analysis into peptides that can be used to identify
therapeutic targets in cancer patients. We demonstrate TransGene on 240 samples from The
Cancer Genome Atlas (TCGA) Prostate Adenocarcinoma (PRAD) cohort. More information
on the mutational rate of this dataset can be seen in Chapter 4. TransGene is developed en-
tirely in python 2.7 and is available at www.github.com/arkal/transgene. TransGene can
be installed using pip, and dockerized versions are available from aarjunrao/transgene.
3.2.2 Introduction
Genomic mutations acquired by cancer cells can result in the production of proteins with amino
acid sequence alterations. Studies have shown that these alterations can be recognized by
autologous T-cells as non-self, resulting in an immune response [21, 114, 74]. These analy-
ses currently use somatic mutations called using next generation sequencing of the tumor and
matched normal DNA, and often use sequencing of the RNA to identify only expressed vari-
ants. Published workflows for neoepitope prediction are specific in their input requirements.
For example, pVAC-Seq [51] require VEP annotated VCFs (with custom downstream plugins),
and INTEGRATE-Neo [121] use fusion gene (Fusion) calls from INTEGRATE. We present
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TransGene, a standalone tool to translate Fusions, SNPEff- [20] or VEP- [75] annotated Single
Nucleotide Variants (SNVs), and short insertions and deletions (INDELs) into peptides that can
be used with any pMHC binding predictor. TransGene enables researchers with more control
over their neoepitope prediction workflows.
3.2.3 The TransGene workflow
TransGene accepts any combination of SNVs, INDELs, and Fusions, and generates the set of
all mutant peptide sequences of a given length derived from those variants. TransGene operates
in 3 steps (3.1A), 1) parse input mutations, 2) process SNVs and INDELs 3) process Fusions.
Identification of expressed variants and potential oxidation of guanine to 8-oxoguanine (OxoG)
events [23] occurs in step 1 if the user provides an input RNA BAM or Whole Genome/Exome
(WGS/WXS) BAM (sequencing data) respectively.
In step 1, TransGene accepts SNVs and INDELs in a single VCF annotated us-
ing SNPEff or VEP. For each VCF record the following sequence ontology terms are ac-
cepted: missense variant, synonymous variant and stop gained for SNVs, frameshift variant,
inframe insertion, inframe deletion, protein altering variant, disruptive inframe insertion, and
disruptive inframe deletion for INDELs. If an RNA BAM is provided, the variant allele fre-
quency (VAF) of the mutant in the expressed transcript is calculated and values below a user-
defined threshold are rejected. If a WGS/WXS BAM is provided, TransGene will identify
OxoG events. We found OxoG filtering using TransGene to be critical for analyzing pediatric
neuroblastoma tumor sequencing data from the TARGET [87] cohort [111], for example. If
sequencing data is provided, TransGene will output a processed VCF file with read coverage,
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Figure 3.1: A) The TransGene workflow. B) A cartoon describing the output ImmunoActive
Regions (IARs) for 4 mutation events. C) A cartoon describing how transgene handles muta-
tions near exon boundaries. It also describes how transgene handles co-expressed mutations
when RNA-Seq data is present. Transcript 1 produces no IARs since there are no reads support-
ing junctions E1:E2 and E2:E4, Transcript 2 produces 2 IARs from junctions E1:E3 and E3:E4,
and Transcript 3 produces 2 IARs from junction E1:E4 (one with both mutations and one with
only the mutant from E1 based on the read support/VAF)
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VAF and a reason for all rejected calls.
Fusion calls are accepted in the BEDPE format with the Fusion name in EnsEMBL
terms in the “name” column, and four additional columns “JunctionSeq1”, “JunctionSeq2”,
“HUGO1” and “HUGO2” containing the inferred junction sequences on either side of the Fu-
sion if available (can be blank) and the HUGO names for each gene. Fusions are optionally
filtered to remove potential false positive events including Fusions between mitochondrial, im-
munoglobulin, or lncRNA genes. Transcriptional read-throughs below a user-defined distance
threshold can be filtered. Once all mutations are read to memory, transgene parses a provided
gencode annotation and genomic FASTA to selectively load transcript sequences and annota-
tions from Fusion- and INDEL-containing genes into memory.
In step 2, TransGene handles the SNVs and INDELs on a per-transcript basis and
prints ImmunoActive Regions (IARs) to an output file. An IAR is the region comprising a
mutant amino acid along with the n− 1 flanking amino acids on either side such that every n-
mer from the region contains the mutant (3.1B). Multiple mutations can be chained together if
the distance between two consecutive events is less than n residues. The IAR for a co-expressed
group is the n− 1 bases on either side of the extreme mutations along with all wild-type and
mutant amino acids that lie between them. If an RNA-Seq BAM is provided, TransGene will
phase co-expressed mutations and filter the set of all combinations into those with expression
evidence (3.1C). Frameshift mutants are assumed to disrupt splicing, and are processed for a
user-provided number of residues downstream to the mutant (30 amino acids by default) in
search of a stop codon. Every generated IAR has a corresponding wildtype peptide that can be
used to calculate the Agretopicity Index [28].
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In step 3, TransGene handles Fusion calls from the BEDPE file, analyzing every
record in the file to identify combinations of transcripts for both Fusion partners. TransGene
infers junction sequences for each combination or use user-provided sequences if provided in
the input BEDPE. If the Fusion results in an in-frame change, the junction sequences are con-
catenated and translated to obtain the IAR. In a frameshift event, the acceptor sequence is the
sequence downstream to the breakpoint on the 3’ partner.
The output from transgene includes a peptide FASTA containing IARs for each pep-
tide length n specified by the user, a corresponding FASTA of wildtype peptides, a processed
VCF and a processed BEDPE. The sequence name for each IAR contains the information about
the gene, transcript, mutation and VAF.
3.2.4 Application of TransGene to a test cohort
We processed 240 samples from the TCGA Prostate Adenocarcinoma (PRAD) cohort [81].
Transgene was run in an automated manner with all Fusion filters, and default values for all other
parameters to produce 9-, 10- and 15-mer-containing IARs. MHCI epitopes are most commonly
9 or 10 amino acids long, and MHCII peptides can be larger than 20 amino acids but netMHC
uses 15 as the size for predicting the binding core. The entire workflow was orchestrated with
the Toil workflow manager [115]. The RNA-Seq BAM and VCF (MuTect2 + VEP) for each
selected sample from the TCGA PRAD cohort were downloaded on the fly from the National
Center for Biotechnology Information (NCBI) Genomics Data Commons(GDC). The Mutect2
VCFs were parsed to retain only calls passing all filters. Fusion data for each sample was
obtained from the supplementary information in the INTEGRATE-Neo paper [121] and parsed
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into a BEDPE file for each sample using a python script. A full explanation (including all
scripts used in this analysis) is provided at https://www.github.com/arkal/TransGene_
supplementary.
The dataset contained 15,430 SNVs and INDELs (0-835/sample), and 2,040 Fusions
(1-47/sample). The median number of SNVs, INDELs and fusions per sample were 50, 5,
and 8 respectively. On average, TransGene accepted 30% of the SNVs and INDELs, based on
expression and 88% of fusions based on all filters. A total of 4,958 9-mer-, 4,998 10-mer- and
4,742 15-mer IARs were generated. The median number of 9-mer IARs from SNVs, INDELs
and Fusions per samples was 9, 0.5, and 5.5 respectively, similar to the values for 10-mers and
15-mers (Supplementary Table 1). Seven samples had co-expressed mutants affecting the same
IAR, of which five affected the same codon (Supplementary Table 2, Supplementary Figures
3.2 and 3.3).
The analysis was run on a Microsoft Azure D14 v2 VM with 112 GB of RAM and
16 2.4GHz Intel Xeon R©E5-2673 v3 (Haswell) processors. Each sample took on average 435
seconds to run. Since TransGene is a novel tool, we do not have another tool to benchmark
this against. However, we can say that 7 minutes of runtime is relatively small compared to
alignment and variant calling, making this a short, yet effective node in a neoepitope prediction
workflow.
3.2.5 Discussion
TransGene is a standalone tool capable of handling patient mutation data with a combina-
tion of sequencing data for detailed putative neoepitope identification. The IARs produced
35
by TransGene can be supplied as input to any pMHC binding prediction tool to identify thera-
peutic neoepitopes for a cancer patient. We believe that TransGene will allow researchers more
freedom in choosing and prioritizing neoepitopes for Adoptive Cell-, and Vaccine-based im-
munotherapies. TransGene works with variant data off the internet (as demonstrated by this
paper), making it a good resource for identification of neoepitope trends across cancer types.
TransGene is an integral part of our in-house workflow for predicting neoepitopes, ProTECT
(Chapter 4).
3.3 The TransGene paper supplementary
3.3.1 Supplementary Figures
Figure 3.2: An IGV screenshot of chromosome X for sample TCGA-CH-5792. The mutations
at positions 48816540 (T>G) and 48816541 (G>C) affect different codons and are fully phased,
hence they affect the same IAR at consecutive residues.
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Figure 3.3: An IGV screenshot of chromosome 8 for sample TCGA-EJ-5525. The mutations
at positions 135542701 (G>T) and 135542702 (C>T) affect different codons and are fully
phased, hence they affect the same IAR at consecutive residues.
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3.3.2 Supplementary Tables
All supplementary tables are provided as separate sheets in a Microsoft excel document and are
named chapter3-supplementary tableX where X is the number of the table.
• Supplementary Table 1: Information on the number of mutants called and accepted for
each input sample, along with the number of 9-mer, 10-mer and 15-mer IARs predicted.
• Supplementary Table 2: Co-Expressed variants detected in the cohort. A) Co-expressed
variants within 9 amino acids of each other, affecting the same 10-mer IAR. B) Co-
expressed variants within 3 amino acids of each other, affecting the same codon.
38
Chapter 4
ProTECT: Prediction of T-cell Epitopes for
Cancer Therapy
4.1 Introduction
This chapter describes the ProTECT pipeline. ProTECT, an acronym for Prediction of T-
cell Epitopes for Cancer Therapy, is a computational workflow used to identify short tumor-
produced peptides of immunotherapeutic significance in cancer patients in a scalable, auto-
mated, reproducible, and efficient manner. The development of ProTECT was driven by the
lack of tools in the field to predict cancer neoepitopes. Since I started my work on ProTECT,
two tools, pVAC-Seq [51] and INTEGRATE-Neo [121] were published. pVAC-Seq generates a
filtered list of neoepitope candidates from SNVs and INDELs, and INTEGRATE-Neo identified
a list of neoepitopes from Fusion genes. Neither of these tools are automated or process data
from FASTQs.
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I identified every required tool (with ideal input parameters) for every module used
in the pipeline, and developed the remaining required modules that had no off-the-shelf tool
– TransGene (chapter 3) to translate genomic mutations into peptides, and Rankboost to rank
the plethora of peptide:MHC (pMHC) predictions made for a sample. I containerized each
module into individual Docker images tagged with the version such that the pipeline would
use reproducible modules. I wrote the entire pipeline in the Toil framework, in the form of
individual packages for each major step in the pipeline. This allows users to easily use my code
to make new custom pipelines. I wrote all the auxiliary code required to process outputs from
modules into the input for others allowing ProTECT to run with no manual intervention. I made
the pipeline available on the Python Package Index (PyPI) for greater availability.
In addition to all of the above, I mentored/oversaw the contribution of the following
individuals. Jacob Pfeil (Lab roton/early addition to the lab at the time) developed the first
pass at Fusion support for ProTECT. Christine Cho, Danlin Lillemark, and Shreya Guha (sum-
mer high school interns through the UCSC SIP program in Summer 2016) curated a list of
immune pathways implicated with tumor progression or regression. Ada Madejska (undergrad-
uate research assistant) completed the work started by the high schoolers and converted it into
a reporting module in ProTECT. Ada also identified clinical trials involving CAR therapies and
made that an additional report output by ProTECT. Aisling O’Farrell (undergraduate research
assistant) created a working dockerized version of ProTECT with additional help from Christo-
pher Ketchum from the Genomics Institute. David Stewart (undergraduate research assistant)
implemented support for mixing and matching mutation callers and specifying thresholds for
consensus calling providing users better control over the variants called by ProTECT.
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4.2 The ProTECT paper
4.2.1 Abstract
Somatic mutations in cancers affecting protein coding genes can give rise to potentially ther-
apeutic neoepitopes. These neoepitopes can guide Adoptive Cell therapies (ACTs) and Pep-
tide Vaccines (PVs) to selectively target tumor cells in the body using autologous patient cy-
totoxic T-cells. Currently, researchers have to independently align their data, call somatic
mutations and haplotype the patient’s HLA to use existing neoepitope prediction tools. We
present ProTECT, a fully automated, reproducible, scalable, and efficient end-to-end analy-
sis pipeline to identify and rank therapeutically relevant tumor neoepitopes in terms of im-
munogenicity starting directly from patient sequencing data. The ProTECT pipeline encom-
passes alignment, HLA haplotyping, mutation calling (single nucleotide variants, short inser-
tions and deletions, and gene fusions), pMHC binding prediction, and ranking of final candi-
dates. ProTECT also allows the user to start from pre-computed data. We demonstrate Pro-
TECT on 326 samples from the TCGA Prostate Adenocarcinoma cohort, and compare it with
published tools. ProTECT processes an average TCGA sample starting from input FASTQs
in 26 minutes when run in a batch of 50 samples on our cluster. ProTECT is available at
https://www.github.com/BD2KGenomics/protect.
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4.2.2 Introduction
Tumor recognition by the adaptive immune system has been known as early as 1988, when
Muul et.al. described a 55% objective response rate in a cohort of melanoma samples [79].
However, at the time, T-cell responses were observed to be short lived, often lasting very few
days. Later studies showed that tumors are adept at suppressing the immune system in many
ways [34, 105, 36, 39].
Checkpoint blockade therapy has seen a great increase in interest in the past few years
with numerous drugs being approved by the FDA for clinical treatment [91, 15, 50]. Prevention
of PD-1:PD-L1 [5] and CTLA-4:B7.1/2 [17] binding via monoclonal antibodies re-enables the
immune attack against the tumor, however it can leave the patient open to development of
autoimmunity or other toxicities associated with unchecked immune action [95, 31].
Adoptive Cell Therapies (ACTs) use T-cells specifically targeted against the tumor to
reduce the collateral damage associated with conventional therapies. Tumor Infiltrating Lym-
phocytes (TILs) from patient tumors can be activated and expanded in-vitro using minced autol-
ogous tumor or experimentally primed autologous dendritic cells [94, 119] to selectively target
cell-surface MHC-presented antigen produced by the tumor. Cancer vaccines attempt to pro-
duce the same result as ACT therapies by stimulating dendritic cells in-vivo via synthetically
produced peptides (or coding RNA) delivered subcutaneously to the patient [85, 97]. This re-
moves the requirement for extracting and assaying T-Cell interactions in-vitro. Experimentally
primed Dendritic cells and Peptide vaccine therapies require prior knowledge of the mutations
in the tumor to identify the potentially targetable sequence. This can be achieved using a com-
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bination of Next Generation Sequencing (NGS) and bioinformatics.
Currently, there are two published methods to identify neoepitopes from tumor vari-
ants. pVAC-Seq [51] is an automated bioinformatics pipeline that identifies neoepitopes gener-
ated from a pre-computed VCF file of variants annotated using VEP [75] (and some specialized
plug-ins). INTEGRATE-Neo [121] identifies neoepitopes from fusion genes provided in a pre-
computed BEDPE file. Both these tools require a user to previously align the sequencing data
to a reference of choice and call variants before following the same logical paradigm of iden-
tifying mutant peptides and predicting pMHC binding affinity (often via netMHC [71]). Other
unpublished (or proprietary) pipelines exist [2], that differ in their degree of automation, input
mutation type and annotation, and presence or absence of a ranking schema, however to our
knowledge, none of them fully automate the process from end-to end, beginning at the raw
FASTQs emitted by the sequencer.
We describe ProTECT, a fully automated, open-source tool for the Prediction of T-
cell Epitopes for Cancer Therapy. ProTECT accepts an input trio of sequencing data from
a patient consisting of the tumor DNA, normal DNA, and the tumor RNA sequencing reads
in the FASTQ format and processes the data from end-to-end including Alignment, in-silico
HLA haplotyping, expression profiling, mutation calling and neoepitope prediction. We showed
the utility of ProTECT in a previous publication where we identified a potentially therapeutic
neoepitope from the hotspot ALK:R1275Q mutant in pediatric Neuroblastoma [111] (Chapter
5). The prediction was biochemically validated and was also shown to be recognized by PBMCs
from HLA-matched donors using a tetramer assay.
To demonstrate ProTECT in this manuscript, we use the Prostate Adenocarcinoma
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(PRAD) cohort from The Cancer Genome Atlas (TCGA) project [81]. The PRAD cohort con-
sists of 500 patients in total, 331 of which have trios of genomic data (Tumor DNA, Normal
DNA, and Tumor RNA). The TCGA PRAD cohort has an average of 24.8 exonic mutations per
sample [66] and 157 of the 500 are predicted to contain fusion transcript [118]. In addition to
the PRAD analysis, we compare our results to the published pVAC-Seq and INTEGRATE-Neo
pipelines.
4.2.3 The ProTECT pipeline
4.2.3.1 Description
ProTECT identifies therapeutically significant neoepitopes in a given samples using a series of
methods that are orchestrated in a single automated pipeline using the Toil workflow manager
[115]. Input sequencing data is processed to identify the patient’s HLA haplotype, and to gener-
ate alignments against a reference genome (sequence alignment). The aligned reads are used to
identify somatic variants (mutation calling), and to estimate the gene- and isoform-level expres-
sion within the tumor (expression profiling). Somatic variants are translated into short peptides
that contain a new sequence (or neoepitope) that isn’t seen in the self-immunopeptidome. The
binding affinity for these peptides to MHC alleles in the patient’s haplotype is assayed in-silico
and the final output is a ranked list of sequences that can be used to guide a neoepitope-based
immune therapy. The schematic for the ProTECT workflow is shown in figure4.1. For con-
venience, ProTECT can also be run using pre-computed alignments, or using pre-computed
somatic variants.
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Figure 4.1: A schematic description of the ProTECT workflow. ProTECT can process FASTQs
all the way through the prediction of ImmunoActive Regions, including alignment, HLA Haplo-
typing, variant calling, expression estimation, mutation translation, and pMHC binding affinity
prediction. ProTECT also allows users to provide pre-computed inputs for various steps instead.
4.2.3.1.1 Sequence Alignment
Variant calling on sequencing data requires the input FASTQs to be aligned to a genomic ref-
erence. DNA sequence alignment on the Tumor and Normal sequencing data is carried out
using the burrows wheeler aligner (BWA) [69] with default parameters. The aligned SAM file
is processed to properly format the header, and is then converted to a coordinate-sorted BAM
file with a corresponding index. RNA sequence alignment is carried out using the ultra-fast
aligner, STAR [27]. The parameters for the run are optimized for fusion detection (Supplemen-
tary note 1). ProTECT creates both a genome-mapped BAM (Used in variant calling) and a
transcriptome-mapped one (Used in expression estimation).
Alternatively, ProTECT accepts pre-aligned BAMs as an input if the MHC haplotype
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is provided as well. ProTECT assumes that the user has aligned the DNA and RNA using the
same reference genome.
4.2.3.1.2 Haplotyping
The HLA haplotype of the patient is crucial information when predicting neoepitopes as TCRs
will only react favorably so self-MHC -displayed neoepitopes. The HLA haplotype is predicted
using PHLAT [6], taking each input source of sequencing data. A consensus haplotype is gener-
ated based on agreement between the three individual haplotype predictions. Due to limitations
in the tool, we only predict HLA-A, HLA-B and HLA-C for MHCI, and HLA-DPA/B and
HLA-DRB for MHCII.
4.2.3.1.3 Expression profiling
The gene- and isoform-level expression profiles for the patient are used to identify which
variant-containing genes and transcripts are expressed in good quantities (relative to other ex-
pressed molecules). This is estimated using RSEM [68] with default parameters.
4.2.3.1.4 Variant Calling
SNV calling occurs in a per-chromosome manner across any combination of 5 mutation pre-
diction algorithms, MuTECT [18], MuSE [35], RADIA [90], Somatic Sniper [65], and Strelka
[102]. The choice of mutation callers was guided by the ICGC DREAM mutation calling chal-
lenge [33]. The SNV predictions from the callers are merged into a common file and only events
supported by n or more predictors (user-provided, or (x+1)/2 where x is the number of input
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predictors) advance to the translation step.
In addition to SNV calling, Strelka also predicts somatic INDELs. These INDELs are
added to the same VCF that contains the consensus-called SNVs.
Fusion genes are predicted using STAR-Fusion [40] with default parameters. The
fusions are then annotated using Fusion-Inspector [3] along with an optional assembly step
using Trinity [41].
4.2.3.1.5 Mutation Translation
Variants called in the previous step need to be translated into peptides that can be assayed in-
silico for MHC binding affinity. MHCI molecules generally bind to 9- and 10-mer peptides and
the binding groove of an MHCII molecule is considered to be about 15 amino acids (This value
is used by our pMHC binding prediction predictor).
SNVs are translated from genomic coordinates to proteomic coordinates using SNPEff
[19] and coding variants are processed using TransGene (Chapter 3). TransGene filters the input
SNPEff-ed VCF to exclude non-expressed calls based on the gene expression data. Mutations
lying within 27, 30, and 45 bp of each other (for 9-mer-, 10-mer- and 15-mer-containing pep-
tides respectively) are chained together into an “ImmunoActive region” (IAR), or a region that
will potentially produce an immunogenic peptide. These events are phased using the RNA-Seq
to ensure that they truly are co-expressed on the same chromosome.
Fusion peptides are generated using the breakpoints present in the input BEDPE file.
TransGene uses provided junction sequences or infers them from the input annotation file. The
predicted IAR contains (n−1)×3 ∀n ∈ {9,10,15} bp on either side of the fusion junction.
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TransGene outputs 10 files in total, A filtered VCF, potential 9-, 10- and 15-mer
neoepitopes as peptide FASTQs, the corresponding 9-, 10- and 15-mer wild type epitopes, and
a map file for each of the tumor FASTQs that maps each peptide FASTQ name to the gene,
mutation, and list of transcript isoforms of origin.
4.2.3.1.6 MHC:Peptide binding prediction
The predicted neoepitopes are assayed against each MHCI (9- and 10-mers) and MHCII (15-
mers) predicted to be in the patient’s HLA haplotype using the IEDB MHCI and MHCII binding
predictions tools.
The IEDB tools run a panel of methods [83, 82, 58, 14, 86, 120, 110] on each input
query (peptide FASTQ + MHC allele) and provide a consensus “percentile rank” that describes
on average, how well did each peptide predict to bind against a background set of 100,000
UniPROT derived peptides. pMHC calls predicted to bind within the top 5% of all binders for
that MHC are selected for further study.
The normal counterpart for each selected neoepitope is then assayed against the MHC(s)
identified to bind with the neoepitope. The data is then tabulated into one table each for MHCI
and MHCII.
4.2.3.1.7 Neo-epitope ranking
Neoepitope:MHC calls are consolidated by the candidate IAR of origin. IARs are ranked using a
boosting strategy that rewards candidates satisfying certain biologically relevant criteria includ-
ing the number of calls originating from the IAR (diversity), the number of MHCs stimulated by
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peptides from the region (promiscuity), the combined expression of the isoforms displaying the
neoepitope-generating mutation, the number of neoepitopes in the region predicted to bind to
an MHC better than their wild type counterpart, and the number of events where a 10-mer, and
a 9-mer subset of it both bind well to the MHC (only in peptide:MHCI ranking). The ranked
results are tabulated into a single file that can be used to guide a neoepitope based therapy. An
output table is generated for MHCI using the 9- and 10-mer pMHC calls, and for MHCII using
the 15-mer calls. The table contains information for each potential IAR including the amino
acid sequence, numeric values for each of the ranking criteria, the final rank, and the list of
binding MHCs.
4.2.3.2 Reproducibility
Every tool used the pipeline, from established aligners to the in-house script used to translate
mutations, is wrapped in a Docker image [89]. Docker allows developers to wrap software
along with all requirements into an image, that can be instantiated into a container on any
other machine. The software within the container is guaranteed to run in the same manner
on any machine, under the same environmental constraints. Since every tool in ProTECT is
containerized using Docker, ProTECT results from different machines are directly comparable
to each other.
4.2.3.3 Automation, Scalability and Efficiency
ProTECT is built to be run end-to-end without any user intervention. ProTECT is written in the
Toil framework and will attempt to run the pipeline on the given input samples in a resource-
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efficient manner. The pluggable backend Toil APIs allow ProTECT to run on a single machine,
a grid engine cluster, or a mesos cluster setup on a local network, or on AWS. Toil allows users
to deploy scripts on Azure and the Google cloud as well, however ProTECT does not support
these platforms. Users provide ProTECT a configuration file that details the input files, and the
various indexes and versions of tools to use during the run. ProTECT downloads the files to a
“file store” and then spawns a graph of jobs for each input sample culminating in a ranked list
of epitopes. The nodes in the graph are tuned to request an appropriate number of CPUs (for
multithreaded jobs), memory and disk space – And Toil ensures that these jobs are parallelized
to the maximum extent.
4.2.4 Materials
4.2.4.1 Input samples
Genomic Trio (Tumor DNA, Normal DNA, and Tumor RNA) BAMs from 326 samples in the
Cancer Genome Atlas (TCGA) Prostate Adenocarcinoma (PRAD) cohort were downloaded
from the Genomics Data Commons (GDC) at the National Cancer Institute using the GDC data
transfer tool. The downloaded BAM files were converted back to FASTQ using the SamToFastq
module from Picard version 1.125 [1]. MHCI haplotype calls using POLYSOLVER [106] for
all samples for benchmarking were obtained and used with the permission of Dr. Catherine Wu.
Genomic Trios from 3 additional samples (Mel-21, Mel-38, Mel-218) were down-
loaded from the SRA [67] via Bioproject PRJNA278450/dbGaP accession phs001005. These
patients were diagnosed with stage III resected cutaneous melanoma and had all previously re-
ceived ipilimumab. Data from seven HLA-A*02:01 restricted vaccines tested for each patient
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were obtained from the supplementary information of the original manuscript [16].
The input data for the INTEGRATE-Neo comparison included haplotype and fusion
calls from parsed from 240 samples from the supplementary data of the publication. Fusion
gene predictions for each samples were extracted from Supplementary Excel Sheet 1 parsed
into individual BEDPE files. HLA haplotypes were extracted from Supplementary Excel Sheet
3 into individual haplotype list files with one MHC allele per line.
4.2.4.2 Tool indexes
Indexes for the various tools were generated using the hg38 reference sequence obtained from
the UCSC genome browser [60]. GENCODE [43] v25 was chosen as the reference annotation
and was used to filter the background SNV databases and SNPEff. Every hg38 index used in the
analysis is available in our AWS S3 bucket, ‘protect-data’. A detailed list of commands used to
create the various indexes is available in the same bucket in the README.
4.2.4.3 Compute Infrastructure
The 326-sample PRAD analysis and the INTEGRATE-Neo comparison were both conducted
on a Mesos [48] cluster with one leader (12 CPUs, 62GB RAM, 500GB Local disk) and eight
identical agents (56 CPUs, 250GB RAM, 1.8TB local disk). The pVAC-Seq comparison on the
3 Melanoma samples was conducted on an Amazon Web Services EC2 c3.8xlarge instance (32
CPUs, 60GB Ram, 640GB Local disk) and the data was stored securely using SSE-C encryption
on S3.
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4.2.5 Methods
We ran 3 experiments to demonstrate our pipeline. The first experiment was run on 326 samples
from the TCGA PRAD cohort and highlights the scalability, efficiency and utility of ProTECT.
The second experiment compares ProTECT to the published SNV- and INDEL-based neoepi-
tope prediction pipeline, pVAC-Seq. The third experiment compares ProTECT to the published
fusion-based neoepitope predictor, INTEGRATE-Neo. In all experiments, ProTECT was run
using a consensus of 2 out of 5 mutation callers and all TransGene fusion filters to remove
inter-mitochondrial, inter-immunoglobulin, 5’ lncRNA, and transcriptional readthrough events.
Results were tabulated using a mix of python scripts and manual curation on a local machine.
4.2.5.1 326-sample PRAD compute
The 326 samples were run in batches of 1, 2, 5, 10, 20, or 50 samples in order to gauge the
efficiency and scalability of toil. Each batch size was run 5 times with unique samples to
normalize the runtime information. The configuration file for each run was generated from a
template containing all the required tool options and paths to the input reference files on the
NFS storage server. Each batch was run once on the mesos cluster using all nodes and an NFS-
based Toil file job store to save the state of the pipeline. The five single-sample batches were
also run separately without mesos on individual nodes of the cluster using an NFS-based Toil
file job store to document the time taken per sample on a single machine.
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4.2.5.2 Comparison with PVAC-Seq
To compare our results with PVAC-Seq, we ran ProTECT on the input samples on AWS EC2
using an S3-based cloud job store. The input configuration for the run included paths to HG38-
mapped reference files from our AWS S3 bucket ‘protect-data’ and paths to the input FASTQ
files in another secure bucket. The results were stored on AWS S3 in the same bucket as the
input. This analysis was conducted consistent with the mandatory cloud data use limitations on
the input dataset.
4.2.5.3 Comparison with INTEGRATE-Neo
To compare our results with INTEGRATE-Neo, we had to convert the data from the supplement
into files acceptable by ProTECT (Methods). The initial input configuration file consisted of
links to the fusion BEDPE for each of 240 samples, along with haplotype and expression data
called from the 326 sample run. The final analysis included fusion and inferred haplotype calls
from 83 INTEGRATE-Neo samples along with ProTECT expression estimates. All ProTECT
runs were conducted on the mesos cluster.
4.2.6 Results and Discussion
4.2.6.1 326 Sample run
To describe the scalability, utility and efficiency of ProTECT, we ran ProTECT on a total of 326
genomic trios from the TCGA PRAD cohort. We called a median of 77 SNVs, 3 INDELs, and
7 Fusion Genes per sample, and accepted 19, 1, and 4 respectively for the production of IARs
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(Table 4.1). We identified a median of 11 IARs per sample. Of the 326 samples, 3 samples were
predicted to have no actionable mutants (Expressed missense SNV, INDEL, or fusion). TCGA-
CH-5743 was part of the TCGA data freeze list and was known to have no somatic SNVs or
INDELs. INTEGRATE has 4 fusions called for the sample (including one TMPRSS2-ERG
event) with 1 read support each but ProTECT did not detect any of them. TCGA-G9-6370 was
not in the INTEGRATE list but was expected to have one variant, chr4:88494316G>T, as re-
ported in the TCGA MAF. This call was rejected by both MuTECT and RADIA for insufficient
ALT allele support. TCGA-FC-A66V was not in the data freeze and did not have any INTE-
GRATE calls. Of the remaining 323 with at least 1 actionable mutant, only 4 were predicted
to produce no IARs. The entire results table is submitted as Supplementary Table 1. We de-
tected a total of 12 recurrent gene-fusion pairs (Table 4.2) and 71 recurrent SNVs and INDELs
(Supplementary Table 2).
We detected the well-documented TMPRSS2-ERG fusion gene in 131 samples. We
predicted at least one IAR each arising from 5 of the 10 unique breakpoints predicted (Ta-
ble 4.3). 4 of the breakpoints are located in the 5’ UTR of TMPRSS2 and will not result in
a neoepitope. The last breakpoint we did not call an epitope from has a 5’ intronic break-
point and a 3’ exonic one, and the resulting neoepitope should contain the translated product
from the last few bases of TMPRRS2 Exon 1 and the first bases after the de novo splice ac-
ceptor is reached in ERG. This case is not handled by TransGene at this time. We predict
the IAR “DNSKMALNSEALSVVSED” from the junction chr21:41498119-chr21:38445621
in 37 of the 48 unique samples harboring that junction (11% of the entire cohort). Among
the MHC molecules predicted in the group to bind to a peptide from this IAR are HLA-
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Metric
Called Variants Accepted Variants
MHCI IARs
SNVs INDELs Fusions SNVs INDELs Fusions
Mean 94.74 5.69 8.82 22.67 2.74 4.68 12.85
SD 111.58 28.88 5.68 33.89 18.54 4.45 19.71
Median 77 3 8 19 1 4 11
Min 5 0 0 0 0 0 0
Max 1536 504 49 448 329 46 273
Table 4.1: Statistics for 323 samples with at least 1 accepted variant. We predict at least 1 MHCI
IAR in 319 samples with a median of 11 per sample. As expected, SNVs are the dominant
variant type.
A*02:01 (Allele frequency: 0.26) and HLA-C*07:01 (Allele frequency: 0.17) (Figure 4.7),
two alleles that are frequently seen in Caucasian populations. Similarly, we predict “SGCEER-
GAAGSLISCE” from 22/35 samples with chr21:41507950-chr21:38445621, binding to HLA-
C*07:01, HLA-C*04:01, and HLA-B*44:02 (0.14, 0.12, 0.08 allele frequency respectively)
(Figure 4.10). These results suggest the possibility of a universal epitope for vaccinating pa-
tients with TMPRSS2-ERG. The epitope that will benefit any patient harboring the hotspot
breakpoint and an HLA haplotype capable of detecting a neoepitope produced from that fusion.
Further experimental validation would be required to assess the viability of the two IARs as
vaccine candidates.
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Gene name ENSEMBL Gene name HUGO Count
ENSG00000184012-ENSG00000157554 TMPRSS2-ERG 131
ENSG00000158715-ENSG00000157554 SLC45A3-ERG 7
ENSG00000184012-ENSG00000175832 TMPRSS2-ETV4 6
ENSG00000158715-ENSG00000006468 SLC45A3-ETV1 4
ENSG00000184012-ENSG00000006468 TMPRSS2-ETV1 3
ENSG00000139865-ENSG00000258601 TTC6-RP11-81F13.2 3
ENSG00000167861-ENSG00000243069 HID1-ARHGEF26-AS1 2
ENSG00000146963-ENSG00000006468 LUC7L2-ETV1 2
ENSG00000152894-ENSG00000093144 PTPRK-ECHDC1 2
ENSG00000128891-ENSG00000122565 C15orf57-CBX3 2
ENSG00000184012-ENSG00000110108 TMPRSS2-TMEM109 2
ENSG00000203727-ENSG00000111961 SAMD5-SASH1 2
Table 4.2: Recurrent fusions called by ProTECT. PRAD is characterized by an abundance of
TMPRSS2 fusions with genes in the ETV family (TMPRSS2-ERG being the most popular)
56
B
re
ak
po
in
t
C
ou
nt
5’
br
ea
kp
oi
nt
3’
br
ea
kp
oi
nt
N
eo
ep
ito
pe
ex
pe
ct
ed
?
IA
R
C
ou
nt
21
:4
15
08
08
1-
21
:3
84
45
62
1
12
2
5’
U
T
R
E
xo
n
2
N
o
N
A
21
:4
14
98
11
9-
21
:3
84
45
62
1
48
E
xo
n
2
E
xo
n
2
Y
es
D
N
SK
M
A
L
N
S
E
A
L
SV
V
SE
D
37
21
:4
15
07
95
0-
21
:3
84
45
62
1
35
E
xo
n
1
E
xo
n
2
Y
es
3
SG
C
E
E
R
G
A
A
G
SL
IS
C
E
22
21
:4
15
08
08
1-
21
:3
84
74
12
1
18
5’
U
T
R
In
tr
on
1
N
o
N
A
21
:4
15
06
44
5-
21
:3
84
45
62
1
18
In
tr
on
1
E
xo
n
2
Y
es
1
N
A
21
:4
15
08
08
1-
21
:3
85
84
94
5
11
5’
U
T
R
5’
U
T
R
N
o
N
A
21
:4
14
98
11
9-
21
:3
84
74
12
1
7
E
xo
n2
In
tr
on
1
Y
es
2
D
N
SK
M
A
L
N
S
L
N
SI
D
D
A
Q
L
7
21
:4
15
08
08
1-
21
:3
84
23
56
1
7
5’
U
T
R
E
xo
n
3
N
o
N
A
21
:4
14
98
11
9-
21
:3
84
23
56
1
4
E
xo
n2
E
xo
n
3
Y
es
3
D
N
SK
M
A
L
N
S
E
L
S
1
21
:4
14
94
35
6-
21
:3
84
45
62
1
3
E
xo
n
3
E
xo
n
2
Y
es
3
SP
SG
T
V
C
T
S
R
SL
IS
C
E
3
Ta
bl
e
4.
3:
R
ec
ur
re
nt
T
M
PR
SS
2-
E
R
G
br
ea
kp
oi
nt
si
n
th
e
co
ho
rt
.I
A
R
sf
ro
m
21
:4
14
98
11
9-
21
:3
84
45
62
1
an
d
21
:4
15
07
95
0-
21
:3
84
45
62
1
ar
e
re
cu
rr
en
ts
ug
ge
st
in
g
th
ei
rv
ia
bi
lit
y
un
iv
er
sa
lp
ep
tid
e
va
cc
in
e
ca
nd
id
at
es
.W
e
do
no
te
xp
ec
tt
o
se
e
an
IA
R
fr
om
fu
si
on
s
w
ith
5’
U
T
R
br
ea
kp
oi
nt
s.
1
Tr
an
sG
en
e
ca
nn
ot
ha
nd
le
de
no
vo
sp
lic
e
ac
ce
pt
or
s.
2
A
n
E
pi
to
pe
w
ill
ex
is
tw
he
re
th
e
T
M
PR
SS
2
re
ad
s
in
to
th
e
in
tr
on
of
E
R
G
.3
A
fr
am
es
hi
ft
is
se
en
on
th
e
E
R
G
si
de
of
th
e
fu
si
on
.
57
We detected a number of recurrent mutations in the SPOP gene concordant with pre-
vious reports [81, 8, 11]. We detected 7 unique recurrent variants across 19 samples that map
to 3 different amino acid substitutions in the SPOP protein, p.F133C/V/I/L, p.F102C/V, and
p.W131G (Table 4.4). The mutation at position 133 might be of immunological interest since
Leucine, Isoleucine and Valine have small hydrophobic side-chains and peptides from the 3
IARs may bind to the same MHC molecules in similar configurations. Table 4.5 shows similar
predicted binding affinities of p.F133V/I/L variants to HLA-A*02:01 (as an example) using the
IEDB suite. Samples containing SPOP mutations and samples harboring a TMPRSS2-ERG
fusion are mutually exclusive of one another, suggesting that vaccine therapies against SPOP
and the TMPRSS2-ERG fusion will target different populations of PRAD patients.
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Epitope p.F133V p.F133I p.F133L WT
FVQGKDWGX 1.4 3.4 3 17
VQGKDWGXK 70 71 63 58
QGKDWGXKK 88 85 87 74
GKDWGXKKF 59 53 68 74
KDWGXKKFI 29 30 31 26
DWGXKKFIR 91 90 91 89
WGXKKFIRR 61 54 55 55
GXKKFIRRD 80 82 46 87
XKKFIRRDF 99 98 98 79
Table 4.5: Predicted binding affinities (better than n percent of a background set) of 9-mers
arising from the SPOP mutants affecting p.F133 (FVQGKDWG X KKFIRRDF for X={V, I,
L}) to HLA-A*02:01. The similar chemical properties of Valine, Leucine and Isoleucine lead
to similar binding predictions of neoepitopes substituting them for Phenylalanine. Wildtype
epitope affinity for reference.
We compared our HLA haplotyping results to the POLYSOLVER calls and consistent
with prior work [63], we see the HLA-A*02:01/HLA-A*01:81 miscall in 34 samples. However,
29 of these samples are predicted to be homozygous HLA-A*02:01 by POLYSOLVER so the
effect of this miscall will be to add information to the final ranked IARs from one additional
alleles. Since most IARs contain peptides predicted to bind to more than one allele, this artifact
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called_mhcs
concordant (67.5%)
A (19.3%)
B (6.4%)
C (3.1%)
discordant
differ by >1 (3.7%)
differ by 1
Concordance between our MHC calls and Shukla Et.Al
EDIT CHART
Figure 4.2: HLA Haplotypes called by ProTECT (using PHLAT) are fully concordant with
POLYSOLVER haplotypes in only 67.5% of samples. 28.8% differ by 1 call and 3.7% by 2
calls. A majority of the miscalled HLA-A alleles are a documented PHLAT artifact.
should not skew the results by too much. The remaining 5 samples lacked an HLA-A*01:01
call. This means our results are lacking peptide binding affinity predictions for this allele.
Overall, 67.5% of all samples had perfectly concordant haplotypes with POLYSOLVER, 28.8%
differed by 1 allele and 3.7% differed by 2 (Figure 4.2). 28.8% of the second group consisted
of the miscall mentioned above. Other highly frequent miscalls included HLA-A*26:01 to
HLA-A*25:01 (10.17%) and HLA-B*27:02 to HLA-B*27:05 (8.5%) (Supplementary Tables
13, 14). This effect is out of the scope of this project and ProTECT allows users to provide
pre-computed MHC haplotype calls if they trust another external caller over PHLAT, or if they
have a biologically obtained haplotype.
The 326 samples were run on our cluster in different batch sizes to profile average
sample runtime (Figure 4.3). As the number of samples increases, we see and expected increase
in overall time, but the average time per sample decreases drastically. We processed samples
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Figure 4.3: Average runtimes on our cluster when ProTECT is run in a batch of ‘n’ samples.
Each batch size is run with 5 unique sample sets and the range of runtimes is described by the
whiskers at each datapoint. The grey bar describes the result of running ProTECT on a single
sample on one machine. ProTECT takes considerably less time on average when run in a large
group.
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from end-to-end at a rate of ≈ 26 minutes per sample when running in a batch of 50 samples.
4.2.6.2 Comparison with published callers
We ran ProTECT on three melanoma samples that were used to benchmark pVAC-Seq. We
called the three expected immunogenic variants in each of the three samples. In some cases,
we even predicted the expected variant in a sub-sample where the original paper missed it
(E.g. The E153K variant in CDKN2A in the Lymph Node of Mel-21) (Table 4.6). Overall, we
ranked IARs containing the expected variants relatively highly (in the top 15-20%) except in
Mel218. One reason that could explain this result is that we are looking at all epitopes showing
good predicted binding to every MHC alleles in the patient’s haplotype, while the clinical trial
focused on HLA-A*02:01-restricted peptides.
In addition to the expected variants, we also provided a larger ranked set of possible
candidates that broaden the spectrum of testable epitopes. The data for all 7 tested peptides is
provided in Supplementary Table 3 and the ProTECT results for all samples are provided in
Supplementary Tables 4-11.
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0 100620
ProTECT INTEGRATE
Min read support = 1
433 29187
ProTECT
INTEGRATE
Min read support = 5
ProTECT rejects some INTEGRATE calls
Figure 4.4: Fusion calls between ProTECT (STAR + Fusion-Inspector) are not concordant with
INTEGRATE. A large number of INTEGRATE fusions have read support <5 (left) however
some of these are called by ProTECT with >5 support (right).
We compared our fusion prediction accuracy with the published INTEGRATE-Neo.
The test dataset consists of INTEGRATE-Neo-predicted epitopes from 240 samples that have
not been validated using any biological experiments. We use the INTEGRATE-neo calls as a
ground truth for or comparison. We first attempted to compare our ProTECT fusions with the
fusion calls generated from INTEGRATE. The overlap between the two was very poor and a
quick look at the reported read support for the INTEGRATE calls in the form of “spanning
reads” showed that a lot of fusions were called with less than 5 read support. Figure 4.4 shows
the overlap between ProTECT predicted fusions and INTEGRATE with a minimum of 1- and
5-read support. Furthermore, the MHC haplotypes called in the paper (using HLAMiner [117])
showed very little concordance with the POLYSOLVER and ProTECT-called alleles (Figure
4.5). 61 of the unique MHC alleles called did not match any of the other two callers and
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2 141
ProTECT POLYSOLVER
INTEGRATE-Neo
INTEGRATE-Neo HLA calls have low overlap with ProTECT and POLYSOLVER
Figure 4.5: HLA haplotypes called by HLAMiner in the INTEGRATE-Neo paper have very
low overlap with ProTECT and POLYSOLVER.
0 100620ProTECT INTEGRATE
Overlap between ProTECT (with INTEGRATE inputs) and INTEGRATE calls
0 18137ProTECT INTEGRATE-Neo
Overlap between ProTECT IARs and INTEGRATE-Neo epitopes
Figure 4.6: ProTECT rejects 100/720 INTEGRATE calls for being transcriptional readthroughs
(92) or for having a 5’ non-coding RNA partner (8) (Left). ProTECT predicts 137 of the ex-
pected 155 epitopes called by INTEGRATE-Neo (Right).
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41 matched both. 2 alleles were common between ProTECT and INTEGRATE only, and 1
between INTEGRATE and POLYSOLVER. In order to conduct a more comparable analysis, we
re-ran ProTECT with the INTEGRATE fusion calls and the scraped MHC haplotypes from the
INTEGRATE-Neo supplementary. ProTECT rejected 100 of the 620 samples as transcriptional
readthroughs (92) or for having a 5’ non-coding RNA partner (8) (Figure 4.6). The remaining
fusions were predicted by INTEGRATE-Neo to produce 155 neoepitopes. ProTECT correctly
identified 137 of these neoepitopes as IARs and rejected the remaining 18 for scoring below
the 5% threshold (13), having a 5’ breakpoint in the UTR(4), or for not having a 5’ non-coding
partner (1) (Supplementary table 12, Figure 4.6). We believe that easing our 5% filter will
increase the number of false positives called and stand by our decision to reject all these calls.
The epitopes predicted from the 4 fusions arising from the 5’UTR breakpoints align
with IARs predicted from the same breakpoint but with a different 5’gene partner at the same
locus (Figures 4.8 and 4.9). This artifact might be a “mis-annotation” arising due to differences
between our GENCODE annotation and the annotation used by INTEGRATE. This highlights
the importance of processing every aspect of a neoantigen prediction pipeline using a standard
genomic reference.
4.2.7 Conclusion
We have described an efficient, automated, and portable workflow for the prediction of neoepi-
tope candidates that can guide vaccine-based or adoptive cell therapy. We have shown that
ProTECT scales well on a parallel processing environment and shows great efficiency gains as
the number of samples processed in a batch increases. On average, we processed a sample from
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end-to-end in 26 minutes when we ran 50 samples in a single batch on an 8-node cluster. We
have shown that ProTECT is comparable to existing callers and provides a ranked list of neoepi-
topes arising from SNVs, INDELs and fusion genes. Positive results from a clinical trial were
ranked highly in our results and we retrospectively picked up events missed by the caller used to
guide the trial. We identified recurrent epitopes arising from the well-documented TMPRSS2-
ERG fusion our cohort and theorize the possibility of a universal vaccine for one of the possible
breakpoints. We suggest the possibility of targeting a recurrent SPOP point mutation that af-
fects a completely different cohort of patients without a TMPRSS2-ERG fusion. ProTECT has
immense potential in the rapidly growing cancer vaccine field and further improvements in the
vaccine-design paradigm will ensure the viability of vaccines as a standard-of-care for cancer
therapy in the future.
4.3 Supplementary information
4.3.1 Supplementary Note 1
In order to use the STAR-generated BAM files for fusion detection, we used the following
parameters:
--twopassMode Basic
--outReadsUnmapped None
--chimSegmentMin 12
--chimJunctionOverhangMin 12
--alignSJDBoverhangMin 10
--alignMatesGapMax 200000
--alignIntronMax 200000
--chimSegmentReadGapMax parameter 3
--alignSJstitchMismatchNmax 5 -1 5 5
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4.3.2 Supplementary Tables
All supplementary tables are provided as separate sheets in a Microsoft excel document and are
named chapter4-supplementary tableX where X is the number of the table.
• Supplementary Table 1: The overall metrics for the 326 samples PRAD ProTECT run.
This table includes all metrics captured for each file including input file sizes, and num-
bers of mutations called and accepted, peptides generated, and IARs predicted.
• Supplementary Table 2: The recurrent SNVs and INDELs (n>1) detected in the PRAD
cohort along with the predicted IAR and the frequency of the IAR within the subset of
samples that contained the variant.
• Supplementary Table 3: The ProTECT ranks for all 7 vaccine candidates tested by
Carreno et.al.
• Supplementary Table 4: Ranked IARs predicted by ProTECT using sequencing data
obtained from tumor tissue in the Lymph Node of Mel 218.
• Supplementary Table 5: Ranked IARs predicted by ProTECT using sequencing data
obtained from tumor tissue in the Breast of Mel 38.
• Supplementary Table 6: Ranked IARs predicted by ProTECT using sequencing data
obtained from tumor tissue in the Axillary Lymph Node of Mel 38.
• Supplementary Table 7: Ranked IARs predicted by ProTECT using sequencing data
obtained from tumor tissue in the Abdominal Wall of Mel 38.
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• Supplementary Table 8: Ranked IARs predicted by ProTECT using sequencing data
obtained from tumor tissue in the Skin of Mel 21 obtained in 2013 (with the second RNA
FASTQ pair).
• Supplementary Table 9: Ranked IARs predicted by ProTECT using sequencing data
obtained from tumor tissue in the Skin of Mel 21 obtained in 2013 (with the first RNA
FASTQ pair).
• Supplementary Table 10: Ranked IARs predicted by ProTECT using sequencing data
obtained from tumor tissue in the Skin of Mel 21 obtained in 2012.
• Supplementary Table 11: Ranked IARs predicted by ProTECT using sequencing data
obtained from tumor tissue in the Lymph Node of Mel 21.
• Supplementary Table 12: Detailed reasons for rejecting 18 INTEGRATE-Neo-predicted
neoepitopes. Table A describes 5 breakpoints that were missed due to issues with the 5’
partner and Table B describes the INTEGRATE-Neo- and ProTECT-predicted binding
affinity for the fusion epitope.
• Supplementary Table 13: A detailed list of all samples where PHLAT miscalled one
MHC molecule compared to POLYSOLVER (Ground truth).
• Supplementary Table 14: A detailed list of all samples where PHLAT miscalled two
MHC molecule compared to POLYSOLVER (Ground truth).
4.3.3 Supplementary Figures
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Figure 4.7: MHC alleles called in samples with the chr21:41498119-chr21:38445621
TMPRSS2-ERG breakpoint
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Figure 4.8: A UCSC genome browser showing the 5’ breakpoint (highlighted) for the two
missed epitopes from the ENSG00000231887-ENSG00000003056 fusion. The 5’ partner was
reported as PRH1 but the screenshot shows that the position is in the 5’ UTR for PRH1. The
overlapping PRR4 contains the epitope predicted by INTEGRATE-Neo.
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Figure 4.9: A UCSC genome browser showing the 5’ breakpoint (highlighted) for the two
missed epitopes from the ENSG00000273294-ENSG00000164182 fusion. The 5’ partner was
reported as the readthrough transcript C1QTNF3-AMACR but the screenshot shows that the po-
sition is in the 5’ UTR for C1QTNF3-AMACR. The overlapping AMACR contains the epitope
predicted by INTEGRATE-Neo.
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Figure 4.10: MHC alleles called in samples with the chr21:41507950-chr21:38445621
TMPRSS2-ERG breakpoint
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Chapter 5
Identification of a potentially therapeutic
hotspot neoepitope in Pediatric Neuroblastoma
5.1 Introduction
This work describes a collaborative project between the Haussler Lab at UCSC (Department of
Biomolecular Engineering), the Sgourakis Lab at UCSC (Department of Chemistry and Bio-
chemistry) and the Maris lab at The Children’s Hospital of Philadelphia (Division of Oncology,
Center for Childhood Cancer Research). We demonstrate the clinical utility of ProTECT by
identifying 2 potentially therapeutic peptides arising from the hotspot ALK R1275Q mutation
(≈4% of all NBLs) in high-risk pediatric Neuroblastoma (NBL) from the Therapeutically Ap-
plicable Research to Generate Effective Treatments (TARGET) initiative [87]. The neoepitopes
were predicted to bind strongly to the human HLA-B*15:01 MHC molecule (≈ 8% of Cau-
casian individuals). A T-cell receptor receptive to this peptide and MHC combination (pMHC)
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would theoretically be universal, and can be used to treat any new patient harboring this com-
bination of variant and MHC.
The pMHC binding of the ALK R1275Q derived nonamer (AQDIYRASY) and de-
camer (ADQDIYRASYY) to HLA-B*15:01 were demonstrated biochemically in an Escherichia
coli display system and the reactivity to CD8+ T-cells was demonstrated using Peripheral Blood
Mononuclear Cells (PBMCs) from healthy HLA-B*15:01 matched donors. The non-binding of
the wild-type counterparts (ARDIYRASY and ARDIYRASYY) was demonstrated biochemi-
cally, and molecular modeling provided an explanation for the phenomenon. This work is sig-
nificant because high-risk NBL is generally associated with extremely poor prognosis and has
an overall survival rate of lower than 50% even after intensive chemotherapy, radiation therapy,
or other approved treatments [73, 87]. This work was published in Frontiers in Immunology in
January 2018.
The project involved 3 components – Bioinformatics for the identification of individ-
ual and shared neoepitopes in the TARGET NBL cohort; Biochemistry for the demonstration of
pMHC binding, calculation of binding energy, and molecular modeling (including simulations);
and Cell Biology for the demonstration of CD8+ reactivity to the pMHC combination. The bio-
chemistry work was conducted by the Sgourakis group and the Cell Biology work by the Maris
Group. I conducted the Bioinformatics component with the help of my undergrad research as-
sistant, Ada Madejska. This work included the identification and procurement of relevant and
usable NBL data, analysis via ProTECT, and interpretation of results. I also wrote the sections
concerning the Bioinformatics component in the “Results” and “Materials and Methods”, and
generated Figure 1, supplementary table 1, and supplementary data sheets 1, 2 and 3 (Excel
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tables). The paper and supplementary information are shown below. Supplementary data sheets
1, 2, and 3 are too large to fit in this thesis and can be viewed on the Frontiers in Immunology
website.
5.2 The pediatric NBL study paper
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a recurrent Mutation in anaplastic 
lymphoma Kinase with Distinct 
neoepitope conformations
Jugmohit S. Toor1†, Arjun A. Rao2†, Andrew C. McShan1, Mark Yarmarkovich3,  
Santrupti Nerli1,4, Karissa Yamaguchi1, Ada A. Madejska5, Son Nguyen6, Sarvind Tripathi1, 
John M. Maris3, Sofie R. Salama2,7, David Haussler2,7* and Nikolaos G. Sgourakis1*
1 Department of Chemistry and Biochemistry, University of California, Santa Cruz, Santa Cruz, CA, United States, 
2 Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA, United States, 3 Division of 
Oncology, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 
4 Department of Computer Science, University of California, Santa Cruz, Santa Cruz, CA, United States, 5 Department of 
Molecular, Cell, and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA, United States, 6 Department 
of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, 7 Howard Hughes 
Medical Institute, University of California, Santa Cruz, Santa Cruz, CA, United States
The identification of recurrent human leukocyte antigen (HLA) neoepitopes driving 
T cell responses against tumors poses a significant bottleneck in the development of 
approaches for precision cancer therapeutics. Here, we employ a bioinformatics method, 
Prediction of T Cell Epitopes for Cancer Therapy, to analyze sequencing data from 
neuroblastoma patients and identify a recurrent anaplastic lymphoma kinase mutation 
(ALK R1275Q) that leads to two high affinity neoepitopes when expressed in complex 
with common HLA alleles. Analysis of the X-ray structures of the two peptides bound to 
HLA-B*15:01 reveals drastically different conformations with measurable changes in the 
stability of the protein complexes, while the self-epitope is excluded from binding due 
to steric hindrance in the MHC groove. To evaluate the range of HLA alleles that could 
display the ALK neoepitopes, we used structure-based Rosetta comparative modeling 
calculations, which accurately predict several additional high affinity interactions and 
compare our results with commonly used prediction tools. Subsequent determination of 
the X-ray structure of an HLA-A*01:01 bound neoepitope validates atomic features seen 
in our Rosetta models with respect to key residues relevant for MHC stability and T cell 
receptor recognition. Finally, MHC tetramer staining of peripheral blood mononuclear 
cells from HLA-matched donors shows that the two neoepitopes are recognized by 
CD8+ T cells. This work provides a rational approach toward high-throughput identifica-
tion and further optimization of putative neoantigen/HLA targets with desired recognition 
features for cancer immunotherapy.
Keywords: neoepitopes, Mhc class i, human leukocyte antigens, structural biology, computational biology, 
cancer, T cell receptor
inTrODUcTiOn
Cancer immunotherapy harnesses a patient’s CD4+ and CD8+ T cell responses toward peptide 
neoantigens, which are displayed on the surface of tumor cells by major histocompatibility com-
plex molecules [MHC, termed human leukocyte antigen (HLA) in humans] (1). In the endogenous 
presentation pathway (MHC class I), abundantly expressed intracellular proteins are processed 
by the immunoproteasome and proteasome to yield short peptide fragments that are transported 
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into the endoplasmic reticulum and assembled together with 
the MHC-I heavy chain and β2-microglobulin light chain (β2m) 
by the peptide-loading complex (2). The resulting peptide/MHC 
complexes (p/MHC) are further trafficked through the Golgi 
and eventually displayed on the cell surface, where they are 
surveilled by CD8+ cytotoxic T cells (CTLs) through specific 
interactions with αβ T cell receptors (TCRs) (3). Through this 
process, a large and heterogeneous pool of p/MHC antigens 
is continuously generated in healthy, pathogen infected, or 
tumor cells as a means of displaying a cell’s peptide repertoire 
to the immune system (4). The display of high affinity peptides 
expressed exclusively by the tumor (i.e., neoepitopes) on MHC 
molecules can elicit specific CTL responses, which forms the 
basis of several established immunotherapies against cancers 
(5, 6). One such therapy utilizes in vitro-activated, autologous 
CTLs to selectively target tumor cells (7). Alternatively, vac-
cines can be designed based on known antigens or CTLs can be 
engineered to introduce TCRs with desired specificities toward 
displayed tumor antigens (8). In all cases, neoepitopes derived 
from commonly mutated oncogenic proteins are well-suited 
immunotherapy targets if they have high affinity interactions 
with MHC alleles that are prevalent in the population (9).
Neuroblastoma (NBL) is a widely metastatic form of cancer 
that affects the development of nerve cells that comprise the 
sympathetic nervous system, primarily in patients younger than 
10 years old (10). High-risk NBL has a survival rate of less than 
50% after intensive chemotherapy, radiation therapy, and other 
approved treatments (11). In addition, patients responding posi-
tively to radiation treatments generally do not achieve long-term 
survival and suffer from cancer relapse, often with an increased 
rate of tumor mutations (12). Sequencing studies focusing on 
NBL of all stages indicate a wide spectrum of somatic mutations in 
tumors, which poses a significant challenge for the development 
of targeted therapeutics (13). Notably, mutations in the anaplastic 
lymphoma kinase gene (ALK) have been implicated in 9.2% of 
240 NBL cases with available whole exome, genome, and tran-
scriptome sequencing data from the TARGET (Therapeutically 
Applicable Research to Generate Effective Treatments) initiative 
(12). This and other sequencing data support ALK as the target 
with the highest mutation rate among high-risk NBL patients 
(10, 12, 14). Furthermore, genome sequencing of relapsed 
NBL tumors demonstrates retention of ALK mutations and/or 
acquisition of an ALK mutation in 14/54 (15) and 10/23 (16) 
samples. Such ALK mutations have been shown to hyperactivate 
the RAS–MAPK signaling pathway in NBL, driving cancer 
formation (17). More recent studies have also shown evidence 
of ALK overexpression in NBL tumors making it a viable target 
for CAR-mediated immunotherapy along with other targeted T 
cell therapies (18). Immunotherapy offers an attractive approach 
toward NBL treatment. However, despite significant progress 
in identifying recurrent mutations toward understanding the 
genetic basis of NBL, important molecular details regarding 
derived neoantigen/HLA interactions remain unknown, which 
further limits the development of targeted T cell therapies (11).
Here, we use our recently developed multilayered bioinformat-
ics pipeline, Prediction of T Cell Epitopes for Cancer Therapy 
(ProTECT), to predict therapeutically relevant antigens in NBL 
tumors. ProTECT analysis of 106 patient samples from the NBL 
TARGET cohort identifies a recurring “hotspot” mutation in the 
ALK protein (R1275Q), together with its specificity toward com-
mon HLA alleles. Specifically, two putative peptide sequences with 
the R1275Q mutation, a nonamer and a decamer, are predicted to 
bind HLA-B*15:01 with high affinity according to consensus meth-
ods (19, 20). X-ray structures of the two neoepitopes in complex 
with HLA-B*15:01 reveal a drastic change in peptide conformation, 
which correlates with increased thermal stability of the decamer 
neoepitope/HLA complex. For the self-peptide, unfavorable inter-
actions between the peptide and residues in the MHC-binding 
groove prevent the formation of a stable complex. To evaluate the 
potential of the two ALK neoepitopes to interact with additional 
HLA alleles and predict structural features relevant for recognition 
by TCRs, we develop a high-throughput comparative modeling 
approach using the program Rosetta. Independent crystallographic 
analysis of a decamer-bound HLA-A*01:01 complex reveals a 
peptide conformation, which falls extremely close to our Rosetta 
model (within 1.1 Å backbone RMSD). Finally, tetramer staining of 
peripheral blood mononuclear cells (PBMCs) from HLA-B*15:01-
matched donors followed by flow cytometry analysis shows that 
the two different neoantigen conformations are recognized by 
CD8+ T cells. Taken together, our bioinformatics analysis, in vitro 
and structural characterization, computational modeling, and 
T cell recognition analysis illustrate a powerful approach toward 
high-throughput identification and optimization of broadly dis-
played putative neoantigen/HLA targets for further development 
toward cancer immunotherapy. Results from this approach provide 
strong evidence for broad HLA display of recurrent ALK-derived 
neoantigens expressed in NBL tumors and further suggest that 
the presentation of distinct neoepitope conformations in the HLA 
groove could drive specific CD8+ T cell responses in patients.
resUlTs
identification of ALK r1275Q neoepitopes 
Using ProTecT
A reduced version of our software, ProTECT (Figure 1), was initi-
ally run on a batch of six primary:relapsed NBL sample pairs from 
the TARGET cohort. We find at least one neoepitope-gene rating 
mutation persisting in the relapsed tumor for five of six patients 
(Table S1 and Supplementary Data S1 in Supplementary Material). 
Among these are two well-known hotspot mutations, NRAS Q61K 
and ALK R1275Q (Table S1 in Supplementary Material). We pre-
dicted two HLA-B*15:01-restricted decamer (MAQDIYRASY and 
AQDIYRASYY) and one nonamer (AQDIYRASY) neoepitopes 
arising from ALK R1275Q in sample TARGET-30-PARHAM. The 
predicted binding affinities are better than 0.55, 0.85, and 2.1%, 
respectively, relative to all peptides in a background training set 
(the top 5% ranked peptides are considered true binders by our 
method). While the peptide beginning at M1273 is predicted to 
be the top binder, the two epitopes beginning at A1274 are more 
promising from an immunological perspective since they are 
predicted to be significantly better binders to HLA-B*15:01 than 
their parental self-antigens ARDIYRASYY (10.75 percentile score) 
and ARDIYRASY (35 percentile score).
79
FigUre 1 | Identification of neoantigen targets using the ProTECT pipeline. (a) Flowchart indicating each step of the ProTECT pipeline. Input FASTQs trios per 
sample ultimately give rise to MHC haplotyping and provide a list of candidate neoepitopes for each sample. Abbreviations: TD and ND, tumor and normal DNA, 
respectively; TR, tumor RNA. Predicted tumor–normal single-nucleotide variants (SNVs) are filtered during peptide generation, and again at neoepitope prediction. 
nrange: the range of SNV calls that make it past a certain step; nmed: median number of calls. The primary:relapse pairs were run through a smaller modified version of 
the pipeline that started directly from mutations curated from Eleveld et al. (16). Panels (B,c) show the TARGET neuroblastoma cohort OxoG mutation level. Before 
filtering for OxoG artifacts, we see a predominance of C>A/G>T mutants (B), whereas after filtering we see a marked reduction in the total number of mutations and 
a more balanced nucleotide substitution rate (c).
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Using the full version of the ProTECT software (manuscript 
in preparation), we expanded our study to 100 primary NBL 
samples in the TARGET cohort to collect more complete statis-
tics on ALK R1275Q-derived neoepitopes, and to identify other 
recurrent neoepitopes in NBL (Table S1 and Supplementary Data 
S2 and S3 in Supplementary Material). We identify four addi-
tional samples harboring ALK R1275Q (TARGET-30-PANWRR, 
-PANXJL, -PAPTFZ, and -PAPTLV). None of these samples 
express HLA-B*15:01, but sample PAPTFZ displays a close 
relative, HLA-B*15:03 that is predicted to bind ARDIYRASYY 
and ARDIYRASY with scores of 2.2 and 4.7%, respectively. Two 
samples (PANXJL and PAPTLV) express the high-frequency 
HLA-A*02:01 (20% in Caucasian populations), where an ALK 
R1275Q nonamer (GMAQDIYRA) is predicted to bind HLA-
A*02:01 with a 1.4% score.
All but six of the 100 samples harbor one or more non-
synonymous neoepitope with low percentile scores for at least 
one expressed HLA allele. Among these we identify other recur-
rent mutations, including the ALK mutation F1174L/I/C, present 
in 3/2/1 samples, respectively, and a ZNF717 mutation (Q716), 
present in three samples (Table S1 in Supplementary Material). 
One sample in the cohort expresses NRAS Q61K, an activating 
mutation commonly found in melanoma, thyroid, and colorectal 
cancers. Finally, the NRAS-derived neoepitope ILDTAGKEEY 
arising from a single mutation (Q61K) is predicted to bind the 
common HLA-A*01:01 allele with a statistically significant score 
of 0.35%. Notably, the same HLA-A*01:01/ILDTAGKEEY 
interaction identified by our method has been previously shown 
to elicit a specific T cell response using a melanoma cell line (21).
ALK Tumor neoantigens Form p/Mhc 
complexes with Distinct stabilities In Vitro
The results obtained from ProTECT analysis provide a range of 
therapeutically relevant neoantigen/HLA interactions to validate 
and characterize using biophysical and structural methods. Given 
the extensive genetic evidence supporting a role for ALK mutations 
in NBL tumors (15, 17), we chose to pursue further the interaction 
between ALK R1275Q and HLA-B*15:01. We prepared recombi-
nant HLA-B*15:01 bound to the two ALK-derived neoantigens, 
a nonamer (AQDIYRASY) and a decamer (AQDIYRASYY). 
As a control, we attempted to prepare HLA-B*15:01 with the self-
antigen (ARDIYRASY), which is predicted to have a >10-fold 
reduced binding affinity for the HLA. Peptide/MHC samples 
were refolded from purified Escherichia coli inclusion bodies 
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FigUre 2 | Association of anaplastic lymphoma kinase neoepitopes with recombinant HLA-B*15:01 in vitro. (a) Size exclusion chromatography (SEC) traces of 
MHC samples refolded with nonamer (magenta), decamer (teal), or self (green) peptides. Purification was performed on a HiLoad 16/600 Superdex 75 pg column  
at a flow rate of 2 mL/min. Eluted fractions were probed using SDS-PAGE analysis followed by Coomassie staining (left) and show expected molecular weights for 
HLA-B*15:01 (32.4 kDa) and β2m (11.8 kDa). Further analysis reveals SEC peak identities as protein aggregate (22.8 min), p/MHC complex (29.5 min), and free β2m 
(42.7 min). Attempts at refolding HLA-B*15:01 with the self-peptide did not produce a p/MHC complex (green curve, lack of 29.5 min peak). LC–MS analysis of 
purified nonamer (B) and decamer (c) HLA-B*15:01 complex samples. The top panel shows the chromatogram trace of each complex, while the bottom panel is 
the average relative abundance for the time interval between 9 and 11 min, showing the presence of either the nonamer (observed mass 1,086.70 Da; expected 
mass 1,086.17 Da) or the decamer peptide (observed mass 1,249.71 Da; expected mass 1,249.35 Da) captured in the MHC peptide-binding groove. (D) Differential 
scanning fluorimetry shows that the decamer-bound MHC complex (teal) has an increased thermal stability of 59.3°C relative to the 53.4°C Tm observed for the 
nonamer-bound MHC complex (magenta).
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in the presence of 10-fold molar excess peptide using standard 
methods and purified by size exclusion chromatography (SEC) 
(22). SEC traces of the nonamer and decamer samples show three 
distinct peaks corresponding to protein aggregate (22.8  min), 
p/MHC complex (29.5 min), and free β2m (42.7 min) (Figure 2A). 
Notably, the sample refolded using the self-antigen peptide shows 
only two peaks in the chromatogram, none of which contain non-
aggregated p/MHC molecules (Figure 2A, green trace), further 
suggesting that the affinity of the self-antigen is insufficient to 
promote the formation of a stable complex with the HLA.
To confirm the presence of the neoepitopes in the two MHC 
samples, we performed liquid chromatography–mass spectros-
copy (LC–MS). LC–MS reveals a high relative abundance of the 
correct peptide in each sample, with observed masses of 1,086.70 
and 1,249.71 Da, which agree well with the expected masses of 
the nonamer and decamer, respectively (Figures 2B,C). Thus, we 
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confirm binding of the two tumor neoepitopes to recombinant 
HLA-B*15:01 prepared through in  vitro refolding. To further 
characterize the resulting p/MHC molecules, we used a differ-
ential scanning fluorimetry (DSF) assay, which can accurately 
assess kinetic stability. According to this technique, properly 
folded class I p/MHC complexes show melting temperatures (Tm) 
from 37 to 63°C, which correlate with predicted IC50 values in 
the micromolar to nanomolar range (23). Here, both neoantigen 
p/MHC samples show a clear unfolding transition with a highly 
reproducible Tm of 53.4°C for the nonamer and 59.3°C for the 
decamer complex (Figure 2D), suggesting that the decamer forms 
a higher affinity complex with HLA-B*15:01. Such a difference in 
thermal stabilities of the p/MHC complexes together with previ-
ous observations that peptide length influences its conformation 
within a fixed-length groove is consistent with a hypothesis that 
the two peptides are displayed via distinct binding modes, as 
previously reported for nonamer and decamer peptides sampling 
unique conformations within an MHC groove (24).
structural Plasticity within the Mhc 
Peptide-Binding groove enables Distinct 
neoantigen conformations
To elucidate the structural basis underlying the distinct stabilities 
observed for the two ALK neoepitopes and to further charac-
terize peptide features displayed to TCRs we solved the X-ray 
structures of the nonamer (HLA-B*15:01/β2m/AQDIYRASY) 
(PDB ID 5TXS) and the decamer complex (HLA-B*15:01/β2m/
AQDIYRASYY) (PDB ID 5VZ5). The nonamer complex crystal-
lized in the P212121 space group at a resolution of 1.7 Å, while 
the decamer complex crystallized in the P6122 space group at a 
resolution of 2.6  Å (Table S2 in Supplementary Material). The 
nonamer peptide adopts a canonical extended conformation 
promoted by the N-terminal (Ala1, Gln2) and C-terminal (Tyr9) 
anchors, which are deeply embedded within A/B, and F-pockets 
of the HLA groove (Figures 3A,B), respectively. This anchoring 
results in a “curved” conformation, where the backbone of resi-
dues from Asp3 to Ser8 is pushed toward the upper part of the 
groove while the remaining residues are maintained within the C, 
D, and E pockets (Figure 3B). A survey of previously deposited 
HLA-B*15:01-restricted antigens in the PDB (LEKARGSTY 
derived from Epstein–Barr virus, PDB ID 1XR8; ILGPPGSVY 
derived from human ubiquitin-conjugating enzyme-E2, PDB ID 
1XR9; VQQESSFVM derived from SARS coronavirus, PDB ID 
3C9N) reveals other nonamer epitopes consistently in extended 
conformations (25, 26), in agreement with the conformation of 
the ALK nonamer neoepitope in our X-ray structure (Figures 
S4A–D in Supplementary Material). Furthermore, the overall 
architecture of the B*15:01-binding groove is similar between 
the different structures with heavy atom backbone RMSDs of less 
than 1 Å (Figure S4E in Supplementary Material). Comparison 
between the peptide amino acid sequences reveals excellent agree-
ment with the established HLA-B*15:01-binding motifs, where 
LMQ/AEISTV and FY/LM are preferred/tolerated in anchor 
positions 2 and 9, respectively (Figures S4F,G in Supplementary 
Material). Thus, the X-ray structure of our ALK-derived nonamer 
neoepitope is consistent with established structural features in the 
PDB, suggesting a trend where the peptide backbone conforma-
tion is defined by its length and anchor motifs.
Generally, peptides of length greater than nine amino acids 
either bulge further out of the binding groove or form a “zig-zag” 
conformation (27). However, in our decamer complex structure 
(Figures 3C,D), the peptide adopts a short 310 helical backbone 
conformation from Ile4 to Ala7, as confirmed by an inspection 
of φ/ψ backbone dihedral angles (Figure S1A in Supplementary 
Material). Notably, while the N-terminal anchor residues are iden-
tical in the nonamer and decamer peptide, Tyr10 of the decamer 
replaces Tyr9 of the nonamer as the C-terminal anchor residue 
in a similar conformation (Figures 3B,D). The accommodation 
of a longer peptide sequence within the fixed-size MHC groove is 
thus achieved through the formation of a more compact 310 helix 
for the decamer, relative to the extended nonamer backbone. 
In addition, the 310 helix buries Arg6 further into the MHC 
groove and creates an amphipathic structure where Ile4, Tyr5, 
Ser8, and Tyr9 are oriented toward the solvent (Figure  3D). 
A structural superposition of the nonamer and decamer peptides 
(2.7 Å backbone heavy atom RMSD) highlights the changes in 
residues that are oriented toward the solvent, suggesting that the 
two epitopes display very different surface features for interac-
tions with TCRs (Figures 3E–G).
The compaction of the peptide backbone in the decamer struc-
ture is accompanied by structural adaptations of MHC residues 
in the peptide-binding groove. In particular, in the decamer 
complex the HLA α2 helix undergoes a significant widening 
involving a 5.1 Å displacement of the Cα atom of Arg151. This 
movement is driven by a change in orientation of Arg151, which 
points toward the solvent in the nonamer versus toward the 
groove in the decamer complex (Figures S2A,B in Supplementary 
Material), and the burying of Arg6 further toward the floor of 
the groove. Thus, the addition of a C-terminal Tyr in the peptide 
sequence drastically alters the tertiary structure of the HLA 
complex, driven by a widely different peptide conformation that 
can be accommodated through conformational plasticity within 
a malleable MHC groove.
Key structural parameters extracted from our crystallographic 
analysis provide insights into the increased stability of the 
decamer/HLA complex. Notably, the buried surface area (BSA) 
between HLA-B*15:01 and the decamer peptide is 1,986  Å2, 
relative to 800  Å2 in the nonamer structure. To further dissect 
different structural features for their contributions to p/MHC 
stability, we analyzed all polar (hydrogen bonds, salt bridges, and 
electrostatic interactions) and hydrophobic interactions involv-
ing HLA residues (Figure S5 and Table S3 in Supplementary 
Material). Specifically, the decamer peptide forms additional 
intra-peptide hydrogen bonds as a result of the more compacted 
310 helix conformation. In addition, the decamer participates in 
25 polar and 21 hydrophobic interactions with the MHC residues, 
while the nonamer forms 26 polar but only 11 hydrophobic 
interactions with the groove (Figure S5A in Supplementary 
Material). Specifically, Asp3 and Arg6 of the decamer peptide 
extend further into the groove, forming additional contacts with 
HLA side chains (Figures S5B,C in Supplementary Material). Our 
structural analysis suggests that an increase in the total number 
of intra-peptide hydrogen bonds and hydrophobic packing 
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FigUre 3 | Structural differences in ALK neoepitope displayed by HLA-B*15:01. X-ray structures of the (a) nonamer peptide (PDB ID 5TXS), shown as magenta 
sticks and (c) decamer peptide (PDB ID 5VZ5), shown as cyan sticks embedded into the groove of HLA-B*15:01 molecule. The canonical peptide-binding pockets 
in HLA groove are indicated with letters. (B) Nonamer peptide (magenta sticks) and (D) decamer peptide (cyan sticks) with 2Fo − Fc electron density maps 
contoured at 1.2 σ within the groove of HLA-B*15:01. Yellow dashes represent polar contacts between the peptide and selected MHC residues (green sticks). 
Side-chain orientation of the (e) nonamer peptide and (F) decamer peptide as viewed from the top axis of the peptide highlighting the placement of different 
residues. (g) Structural superposition heavy backbone atoms of the bound nonamer (magenta sticks) and decamer (cyan sticks) neoepitopes (all-atom RMSD of 
4.0 Å) reveal distinct T cell receptor (TCR)-interacting residues between the two neoantigens.
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interactions, consistently with an increase in BSA brought on by 
the more compact 310 helical conformation, leads to an improved 
stability of the decamer complex, as confirmed independently by 
our DSF experiments (Figure 2B).
structural exclusion of the self-antigen 
from the hla-B*15:01 groove
To further evaluate the potential immunogenicity of the ALK 
R1275Q neoepitopes, we compared their affinity for HLA-B*15:01 
relative to the self-peptide (ARDIYRASY). Formation of a stable 
HLA complex displaying the self-peptide would compromise the 
therapeutic relevance of any related neoantigen, due to immune 
tolerance mechanisms that limit the repertoire of responsive 
T  cells. Preliminary attempts to refold HLA-B*15:01 using a 
synthetic nonamer peptide with the parental ALK sequence did 
not result in efficient p/MHC formation, suggesting low binding 
affinity, likely in the micromolar range (Figure 2A, green trace). 
To further explore the basis of this exclusion we performed 
structural modeling of the self-peptide/HLA-B*15:01 complex, 
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FigUre 4 | Structure-based modeling of neoepitope/human leukocyte 
antigen (HLA) interactions. Step 1: A template (blue) peptide/HLA complex 
(X-ray structure) is provided to generate a threaded model with the same 
peptide and different HLA alleles (yellow). HLA residues in the groove within 
3.5 Å of the peptide are colored green. Step 2: Models are refined by energy 
minimization and side-chain repacking of groove and peptide residues (gray). 
Step 3: The average peptide-binding energy is determined by subtracting the 
energy of the unbound HLA and unbound peptide from the energy of the 
peptide bound HLA. <E> represents the average binding energy. The top 10 
lowest energy structures are compared with determine a consensus model.
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using our solved X-ray structure of the nonamer complex as a 
template. We find that performing the reverse Gln to Arg sub-
stitution leads to steric hindrance between the longer Arg2 side 
chain and residues of the MHC-binding groove (Figure S6A in 
Supplementary Material). Despite a careful consideration of all 
possible Arg side-chain rotamers, significant clashes remain with 
Ser67 on the α1 helix, as well as with Ala24, Met45 on the floor 
of the MHC groove (Figure S6A in Supplementary Material). 
As expected from the conservation of peptide residue anchors 
in the A- and B-pockets, we observe similar clashes when the 
self-decamer is modeled with HLA-B*15:01. By contrast, the 
neoepitope Gln2 side chain fits well into the B-pocket, forming 
an additional hydrogen bond Tyr9 from the HLA heavy chain 
(Figure S6B in Supplementary Material, cyan dotted line). Finally, 
we performed detailed structure modeling calculations using 
simultaneous optimization of the peptide backbone in addition 
to the side-chain degrees of freedom and ranked the calculated 
affinities of the three peptides for HLA-B*15:01 according to 
a physically realistic energy function (28). The self-antigen 
complexes yield the least favorable binding energies, followed 
by the nonamer, and finally the decamer complex (Figure S3 in 
Supplementary Material). Thus, our structural analysis is highly 
consistent with our in  vitro results, i.e., that the self-peptide is 
excluded from binding, in sharp contrast with the nonamer and 
decamer neoepitopes which form tight complexes with the HLA.
evaluating the hla-Binding repertoire 
Using comparative Modeling calculations
A patient’s HLA haplotype plays a major role in determining the 
outcome of targeted cancer immunotherapies. Therefore, toward 
expanding the range of individuals that could mount a T  cell 
response to ALK R1275Q neoepitopes, we evaluated the poten-
tial of other HLAs to display the two peptides in  silico. Here, 
we developed and applied a high-throughput approach which 
exploits the availability of our high-resolution X-ray structures 
for the two neoepitopes to simultaneously predict peptide/HLA 
interactions and surface features of peptide residues poised for 
interactions with TCRs. First, we selected a non-redundant set 
of 2,904 HLA alleles (885 HLA-A, 1,405 HLA-B, and 614 HLA-C 
unique sequences) from the EMBL-EBI database (29). We then 
carried out detailed Rosetta comparative modeling calculations 
for each allele, using our experimentally determined HLA-
B*15:01 structures for the nonamer and decamer ALK peptides 
as templates (Figure 4). In contrast to previous structure-based 
peptide/HLA modeling methods which use a flexible peptide 
docking approach (30–32), we used a fixed-peptide backbone 
threading approach followed by energy minimization of the 
interacting peptide and HLA residues to drastically confine 
the docking degrees of freedom. Our approach was motivated 
the observation that the peptide backbone conformation shows 
minimal variance (less than 1.5  Å RMSD) in all nonamer/
HLA-B*15:01 structures reported in the PDB (Figure S4E in 
Supplementary Material). Using this strategy, we extracted 
highly reproducible binding energies for both the nonamer 
and decamer peptides, which are maintained in extended and 
310 helical conformations, respectively, in the resulting models 
(Figure S7 in Supplementary Material). As expected, the HLA-
B*15 alleles rank systematically among the top binders, indicat-
ing a high degree of groove complementarity to both peptides 
(Figure  5; Figure S8A in Supplementary Material, purple). 
Among those, the HLA-B*15:84 allele shows the lowest binding 
energy for the decamer (Figure 5A, black circle), whereas the 
HLA-B*15:107 allele shows the lowest binding energy for the 
nonamer (Figure S8A in Supplementary Material, black circle). 
A total of 116 HLA alleles from all A, B, and C types exhibit lower 
binding energies for both the nonamer and decamer peptides 
than our initial HLA-B*15:01 structural templates (Figure 5A; 
Figure S8A in Supplementary Material, red square), suggesting 
the potential for a broader HLA display repertoire.
To elucidate a sequence bias for specific residues in the HLA-
binding groove that consistently yield more favorable interactions 
with the two peptides, we analyzed the average binding energy 
as a function of sequence identity score (33), calculated rela-
tive to the best binding allele for each peptide (Figure 4). As a 
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FigUre 5 | Continued
negative control, we computed the binding energy for a mock 
HLA allele in which all residues in the MHC-binding groove are 
mutated to Ala. As expected, the mock polyAla HLA exhibits a 
low binding affinity (i.e., high-binding energy) to the peptide and 
is distant from the best binding allele (Figure 5; Figure S8A in 
Supplementary Material, green triangle, top left). We observe an 
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FigUre 5 | Evaluating the human leukocyte antigen (HLA)-binding repertoire of ALK decamer AQDIYRASYY using Rosetta structure-based modeling.  
(a) Rosetta-binding energies calculated from structure modeling of 2,904 unique HLA alleles from the IPD-IMGT/HLA Database (29), for the ALK neoepitope 
decamer (AQDIYRASYY) plotted as a function of sequence similarity to the top binding allele, HLA-B*15:84 (black circle). The binding energy of decamer in our 
HLA-B*15:01 X-ray structure is shown as a reference (red square). A negative control was performed with a mock HLA allele where all residues in the binding groove 
were replaced with Ala (polyAla groove, green triangle), which shows high-binding energy. The corresponding distribution of the HLA alleles on the binding energy 
landscape is captured in the density plot shown on the right. Sequence identity scores were calculated using the BLOSUM62 (33) matrix. Abbreviation: R.E.U., 
Rosetta energy units. (B) Kullback–Leibler sequence logo derived from multiple sequence alignment using ClustalOmega of peptide-binding groove residues from  
all the HLA alleles that exhibit better binding energies than HLA-A*01:01 (brown diamond), indicated with a gray dotted line in panel (a). MHC residues with polar 
contacts to the peptide are denoted with a cyan asterisk with corresponding MHC pocket noted. (c,D) Threaded structural model of HLA-A*01:01 displaying 
decamer peptide. Polar contacts between the MHC groove (gray sticks) and peptide (brown sticks) are shown with cyan dotted lines in the A-, B-, and D-pockets 
(c) or C-, E-, and F-pockets (D). The residue index for each interacting MHC residue is denoted with the corresponding number from panel (B) using subscripts. 
Peptide residues (non-indexed) are labeled without subscripts. Panels (e,F) show polar contacts observed in the A-pocket (e) and F-pocket in the X-ray structure of 
HLA-A*01:01/AQDIYRASYY (PDB ID 6AT9) between the peptide (brown sticks) and residues in the MHC groove (gray sticks). The residue index for each interacting 
MHC residue is denoted with the corresponding number from panel (B) using subscripts. Peptide residues (non-indexed) are labeled without subscripts.
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evident correlation between the computed binding energies and 
sequence similarity to the top binder. Our approach additionally 
allows us to decompose residue specific contributions to overall 
binding energy for each peptide–HLA combination. We find a 
clear trend for both the nonamer and decamer peptides with a set 
of HLA alleles where a bulk of the binding energy is provided by the 
“anchor” positions (Figures S11A,B in Supplementary Material). 
By contrast, the mock polyAla HLA exhibits considerably higher 
binding energy across the entire peptide length (Figures S11A,B 
in Supplementary Material). To elucidate key sequence features 
that allow the peptides to be accommodated in the MHC groove, 
we derived a sequence profile among good binders for the two 
neoepitopes. Such features are highlighted in the Kullback–Leibler 
sequence logo, which reveals preferred residues in the HLA 
peptide-binding groove (Figure 5B; Figure S8B in Supplementary 
Material). According to this metric, highly invariant residues in the 
MHC-binding groove should play an essential role in mediating 
peptide/MHC interactions, as they are consistently observed in 
HLA alleles that exhibit high affinity binding. A close inspection 
of our structural models for the nonamer and decamer bound to a 
common allele in our data set, HLA-A*01:01, reveals similar polar 
contacts, primarily in the A-, B-, and F-pockets, that correlate well 
with the positions of invariant MHC residues (Figures  5C,D; 
Figures S8C,D in Supplementary Material). Specifically, both 
the nonamer and decamer C-terminal anchors employ a similar 
interaction pattern in the F-pocket with conserved Thr, Lys, Trp, 
and Tyr residues of the MHC (Figures  5B,D; Figure S8B,D in 
Supplementary Material).
To test the validity of our structure-based simulations, we 
performed in  vitro refolding of the ALK-derived nonamer and 
decamer peptides with HLA-A*01:01. This allele was chosen 
because it is a high-frequency allele in multiple populations 
worldwide and has been previously shown to form stable recom-
binant p/MHC complexes for structural characterization (34). 
As observed in our previous experiments with HLA-B*15:01 
(Figure  2A), refolding of HLA-A*01:01 with decamer or non-
amer peptide results in a stable p/MHC complex (Figures S8E 
and S9A in Supplementary Material). Further characterization of 
the purified complex reveals a thermal stability of 47.9°C for the 
decamer (Figure S9B in Supplementary Material) and 46.7°C for 
the nonamer (Figure S8F in Supplementary Material), suggesting 
that both ALK neoepitopes have a lower affinity for HLA-A*01:01 
compared with HLA-B*15:01 (Figure 2D, 59.3°C), consistently 
with our binding energy calculations (Figure 5A; Figure S8A in 
Supplementary Material). Although certain HLA and H2 MHC 
alleles have been previously reported to yield partially folded, 
peptide-free molecules with measurable thermal stabilities (35), 
control refolding experiments performed without peptide for 
each of our HLA alleles failed to yield a stable complex. Finally, to 
conclusively test the atomic features predicted by our simulations, 
we determined the X-ray structure of decamer complex HLA-
A*01:01/β2m/AQDIYRASYY (PDB ID 6AT9). The decamer 
complex crystallized in the P32221space group at a resolution 
of 2.9  Å (Table S2 in Supplementary Material). Inspection of 
crystallographic φ/ψ dihedral angles reveals that the peptide 
backbone also adopts a short 310 helix conformation when bound 
to HLA-A*01:01, suggesting that the peptide length is the main 
determinant of its conformation in the groove, and further 
justifying our fixed-backbone modeling approach (Figure S9F in 
Supplementary Material). The peptide conformation in the X-ray 
structure shows excellent agreement with our Rosetta model (1.1 
backbone heavy atom RMSD), with several high-resolution fea-
tures predicted by the model are confirmed by the X-ray, includ-
ing polar contacts within both the A- and F-pockets of the MHC 
groove (Figures 5C–F; Figure S12 in Supplementary Material). 
Specifically, the side-chain hydroxyl group of the peptide Tyr10 
is in contact with the same Tyr, Lys, and Trp side-chain atoms 
from the F-pocket (Figures 5D,F). Finally, in comparison with 
the X-ray structure of the same peptide bound to HLA-B*15:01, 
the side chain of Arg6 is flipped outwards from the groove when 
bound to HLA-A*01:01 altering the peptide surface displayed 
to TCRs (Figures S9D,E in Supplementary Material). Thus, our 
independent X-ray structure corroborates the trend observed in 
our structure-based binding energy simulations and further sup-
ports the potential for other HLA molecules to display the recur-
rent ALK neoepitopes with unique TCR interaction properties.
The Two ALK-Derived neoepitopes are 
recognized by cD8+ T cells
Given the unique conformations and surface features observed 
for the nonamer and decamer peptides, we sought to determine 
whether the two altered-self (i.e., mutated) neoantigens could be 
recognized by CD8+ T cells using a MHC tetramer staining assay 
followed by multichannel flow cytometry analysis. We hypoth-
esized that an HLA-matched donor would be able to recognize 
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altered-self neoepitopes in the periphery, as long as the peptide 
adopts a conformation that can potentiate interactions with TCRs. 
To test this, we acquired PBMCs from two HLA-B*15:01-matched 
healthy donors. For each peptide, we performed a double staining 
experiment using HLA-B*15:01 tetramers conjugated with allo-
phycocyanin (APC) or phycoerythrin (PE), toward identification 
of T cells that recognize each neoepitope. Final cell sorting using 
fluorescence-based detection results in identification of double 
positive populations with a total of 0.012% CD8+ T cells reac-
tive to the nonamer (Figure S13A in Supplementary Material), 
and 0.024% reactive to the decamer epitope (Figure S13B in 
Supplementary Material). Notably, these findings were very simi-
lar between two independent staining experiments using PBMCs 
from individual donors (Figure S13C in Supplementary Material). 
As a control, we additionally performed staining experi ments using 
tetramers made for HLA-B*15:01 complexed with an immuno-
dominant SARS coronavirus-derived epitope (VQQESSFVM) 
(26). For double staining experiments with HLA-B*15:01/SARS 
tetramers, we observe double positive populations correspond-
ing to 0.007 and 0.014% reactive CD8+ T  cells (Figure S13C 
in Supplementary Material). Finally, simultaneous staining 
experiments using nonamer/HLA-B*15:01-PE and decamer/
HLA-B*15:01-PE tetramers did not uncover populations of 
CD8+ T  cells that recognized both epitopes (Figure S13C in 
Supplementary Material). Thus, CD8+ T cells are able to recognize 
both neoepitopes with nominal frequencies that are comparable 
to that of a known immunodominant epitope.
DiscUssiOn
Immunotherapies that stimulate the immune system to attack 
tumors, including immune checkpoint blockade and adoptive 
T cell therapies, have achieved spectacular results in tumor types 
with high mutational burden, such as melanoma (36). However, 
their utility in tumors with lower mutational burden, such as 
those that occur in pediatric cancers, is less clear (37). The devel-
opment of more targeted T cell based immunotherapies to treat 
cancer relies on understanding the molecular basis of neoepitope 
display on tumor cells, in addition to the initiation and regulation 
of cytotoxic CD8+ T  cell responses (38). A current roadblock 
in the development of robust approaches across patients is that 
the HLA locus is extremely polymorphic, and an individual’s 
exact HLA haplotype sculpts the repertoire of epitopes displayed 
to the immune system (5). Moreover, the identification of 
therapeutically relevant antigens in tumors remains extremely 
challenging and is further complicated by the fact that a single 
HLA allele can potentially bind 103–106 distinct peptide epitopes 
(39). Traditionally, in  vitro measurements of affinities between 
an MHC and a potential antigen were achieved by equilibrium 
dialysis (35) and fluorescence polarization experiments (40). 
More recent approaches allow for a global evaluation of the entire 
peptide repertoire, using mass spectroscopy of MHC complexes 
extracted from cell lines expressing a single HLA allele followed 
by bioinformatics analysis (41). Robust alternative strategies 
to identify and characterize neoepitope/HLA complexes with 
desired T cell recognition features would significantly bolster the 
progress of targeted T cell therapies against cancer.
We have recently developed ProTECT, a fully automated and 
freely available tool for predicting expressed neoepitopes based 
on the somatic mutations present in tumor samples. In NBL, a 
common pediatric cancer, ProTECT analysis identifies a range of 
intriguing predicted high affinity neoepitope–HLA targets that 
should be examined in future studies, such as NRAS:Q61K—
HLA-A*01:01 (Table S1 in Supplementary Material), including 
the ALK neoepitopes examined in detail here. Typically, Immune 
Epitope Database (IEDB)-based binding prediction methods 
are biased towards nonamer peptides due to limited number 
of datasets for peptide/MHC-binding affinity measurements 
of shorter or longer peptide lengths (19, 20). Moreover, affin-
ity thresholds for binding based on IC50 values are HLA allele 
specific and range from 60 to 950 nM (42), which could result in 
false negative predictions where weak binding epitopes that may 
be immunogenic are not considered. We attempt to normalize 
for these limitations in ProTECT by using a suite of predictors 
trained on combined and/or allele-specific datasets that consider 
a range of epitope-binding affinities. In our analysis, we find that 
90% of the NBL samples have one or more predicted high affinity 
neoepitope–HLA targets. We sought to characterize the nature 
of the p/MHC interactions resulting from the relatively common 
ALK R1275Q mutation, to lay the groundwork for developing a 
targeted immunotherapy for it, and to develop a pipeline for eval-
uating other promising tumor neoepitopes. Toward these goals, 
we have elucidated the structural characteristics underlying the 
in vitro stability and presentation of two ALK R1275Q-derived 
nonamer and decamer epitopes where the corresponding self-
peptide does not bind to the same HLA groove. We additionally 
developed and applied a high-throughput comparative modeling 
approach to identify additional HLA alleles that could display the 
two neoepitopes and predict their structures with high accuracy, 
toward understanding the link between peptide surface features 
and interactions with TCRs. Finally, we examined the potential 
for the ALK-derived neoepitope/HLA complexes to activate an 
immune response by analyzing CD8+ T  cell recognition from 
HLA-B*15:01-matched donors.
The exact conformation and dynamic features of the peptide 
within the MHC-I-binding groove are known to play pivotal 
roles in recognition by CD8+ T cells, by dictating MHC/peptide-
binding affinity, stability on the cell surface and cross-reactivity 
of interactions with specific TCR molecules (43, 44). Our X-ray 
structures reveal an extreme case of such conformational plasticity, 
in which the addition of a single C-terminal Tyr in the neoantigen 
sequence (AQDIYRASY to AQDIYRASYY) significantly alters 
the peptide conformation (Figures 3E–G). This dramatic change 
relative to the canonical extended structure is highlighted by the 
formation of a 310 helix spanning residues Ile4 to Ala7 (Figure 
S1 in Supplementary Material) and provides a link between pep-
tide conformation and HLA complex stability. Specifically, the 
310 helix leads to an increase in BSA and number of molecular 
interactions between the peptide and HLA side chains (Figure 
S5 in Supplementary Material), in agreement with its increased 
thermal stability (Figure 2D). We additionally observed changes 
in the HLA groove, including a displacement of the α2 helix that 
undergoes a significant widening involving a 5.1  Å movement 
of the Cα atom of Arg151 (Figure S2A,B in Supplementary 
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Material). Our results further support the importance of the α2 
helix, which participates in a myriad of immune processes, such as 
chaperone-mediated peptide loading/editing (45), allele-specific 
antigen presentation (46), and TCR recognition (47), in the con-
text of conformational plasticity of the MHC groove to accom-
modate epitopes of varying length. Finally, structure modeling 
of the self-antigen sequence, in agreement with in vitro refolding 
experiments, shows a sharp contrast in stability relative to the 
neoantigens due to an Arg anchor that cannot be accommodated 
on either an extended or helical backbone conformation. Our 
results provide a rational approach for improving neoepitope/
HLA complex stability and half-life on the cell surface, relative 
to unstable self-epitope/HLA complexes, through optimizing the 
peptide backbone conformation in addition to anchor residue 
interactions. This could ultimately lead to the selection of more 
efficient neoantigens, consistently with previous studies showing 
that the ability of tumor antigens to induce T cell responses that 
prevent tumor relapse correlates with p/MHC stability (6, 48).
As not all cancer patients who harbor a tumor-specific muta-
tion that results in a neoepitope have the same HLA haplotype, 
it would be extremely beneficial to expand the repertoire of HLA 
molecules that bind and present a given therapeutic target. While 
sequence-based tools available at the IEDB (20) can provide highly 
reliable predictions of epitope binding for a range of HLA alleles, 
structural details of the predicted epitope/HLA complex relevant 
for interactions with TCRs are not provided by such methods. 
Complementary methods have been used to model interactions 
within peptide/HLA complexes by leveraging high-resolution 
structural data available in the PDB. These approaches employ 
flexible peptide docking to construct sequence specificity profiles 
by exploring different peptide/HLA combinations (30–32). Here, 
we utilize a comparative modeling approach with a fixed-peptide 
backbone while allowing for side-chain flexibility within the 
HLA groove to screen a large pool of HLA alleles for binding to 
our ALK-derived nonamer and decamer neoantigens (Figure 5; 
Figure S8 in Supplementary Material). High-ranking HLA alleles 
according to Rosetta’s binding energy consistently demonstrate 
a low percentile rank using the epitope prediction method rec-
ommended by IEDB, which further suggests a high probability 
of forming a tight complex with the neoepitopes (Figure S10 in 
Supplementary Material). We subsequently test our binding pre-
dictions and show that both the nonamer and decamer peptides 
form a stable complex with the common HLA-A*01:01 in vitro, 
albeit with decreased stability compared with the HLA-B*15:01 
bound complex (Figure 2D; Figures S8 and S9 in Supplementary 
Material). The accuracy of the Rosetta models is highlighted by 
a comparison to our decamer/HLA-A*01:01 X-ray structure, 
which shows a backbone RMSD of 1.1 Å (Table S5 and Figure 
S12 in Supplementary Material). Our fixed-backbone approach 
is further supported by the observation that the conformation 
of the peptide backbone is maintained among X-ray structures 
containing different, high affinity nonamer peptides bound to 
HLA-B*15:01 (Figure S4E in Supplementary Material). Moreover, 
comparison of the decamer peptide conformation when bound 
to HLA-B*15:01 versus HLA-A*01:01, two alleles that share 
51% of groove residues according to a pairwise sequence align-
ment, shows only a modest change (1.6  Å backbone RMSD) 
(Table S5 in Supplementary Material). In stark contrast, we observe 
a significant conformational change between the nonamer and 
decamer peptides in their crystallographic complexes with the 
same HLA-B*15:01 allele (2.7 Å backbone RMSD). These results 
suggest that peptide length defines the backbone conformation 
through the conservation of anchor residue interactions within 
a fixed-size class I MHC groove. This feature of peptide binding 
allows us to confidently model patient-specific neoepitope/HLA 
interactions in a high-throughput manner, using a single crystal 
structure containing the same peptide as template. Finally, our 
approach allows us to predict surface features of neoepitope/
HLA complexes available for interactions with TCR molecules, 
toward further evaluating their immunogenicity. Within the cur-
rent scope of our method, Rosetta accounts for conformational 
plasticity within the MHC groove by allowing for side-chain 
rotamer and limited backbone flexibility. Thus, accurate mod-
eling of epitope binding is achieved given the template contains 
an MHC groove that is accommodated for a fixed-peptide length 
(i.e., to model a nonamer epitope, a template X-ray structure for 
a nonamer/HLA complex should be used). However, our current 
protocol cannot account for large changes in the backbone of the 
groove, which may be required to model peptides of shorter or 
longer length (49). Future improvements in our structure-based 
prediction procedure that account for this may be achieved using 
Rosetta’s Comparative Modeling (RosettaCM) hybridize (50) or 
RosettaRemodel (51).
To screen for CD8+ T cells that could recognize the tumor 
neoantigens, we focused our analysis on lymphocyte samples 
from healthy donors. We identify populations of CD8+ T cells 
which recognize our two ALK neoepitopes in a highly specific 
manner and with minimum cross-reactivity between them 
(Figures S13A–C in Supplementary Material). We observe 
approximately half the frequency (0.012 and 0.017%) of reactive 
CD8+ T cells for the HLA-B*15:01/nonamer tetramers relative 
to the frequency (0.024 and 0.028%) observed for HLA-B*15:01/
decamer tetramers (Figure S13C in Supplementary Material), 
which may suggest differences in T cell recognition between the 
two epitopes. In addition, the percentage of reactive T cells against 
our two neoepitopes is comparable to values observed for the 
immunodominant SARS epitope (Figure S13C in Supplementary 
Material). While the nominal frequency of T  cells specific for 
most p/MHC molecules ranges from 0.00005 to 0.01% (52, 53), 
our observed values for HLA-B*15 tetramers are within the range 
of specific T cells identified in previous reports of PBMC staining 
of healthy donors using HLA-B*15 tetramers (54). Our staining 
results support the recognition of our putative nonamer and 
decamer neoepitopes by CD8+ T  cells, potentiating the ability 
for the epitopes to drive specific immune responses. Engagement 
of TCR molecules and triggering of signaling of CD8+ T cells 
are driven by interactions between the TCR complementarity-
determining regions and specific peptide/HLA structural motifs 
(44, 55). Our detailed structural characterization provides further 
insight in the unique features that give rise to very distinct inter-
face chemistries displayed by the two neoepitopes. It is likely the 
interplay between HLA complex stability and peptide surface 
features guides the engagement of CD8+ pools by the two neo-
antigens. Future studies in our group aim to identify the TCR(s) 
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that can recognize our HLA displayed ALK neoepitopes toward 
the goal of characterizing the interface of the p/MHC–TCR 
complexes. Structural characterization of ALK p/MHC–TCR 
complexes will allow us to understand how the conformational 
plasticity observed in our nonamer and decamer neoepitopes 
dictates CD8+ T cell recognition (56) toward fostering the devel-
opment of p/MHC–TCR complexes with improved stability in 
the immunological synapse (57).
In summary, we outline a novel approach toward robust, high-
throughput identification and detailed characterization of highly 
stable putative neoantigen/HLA targets with desired T cell recog-
nition features for cancer immunotherapy. Recently established 
technologies have enabled high-throughput, parallel detection of 
T cell specificities for a wide spectrum of epitopes through the 
combinatorial encoding of p/MHC multimers (57). Such meth-
ods have already been applied to monitor the prevalence of T cells 
that are reactive for established tumor epitopes (58). In addition, 
vaccination of cancer patients that display neoantigens can elicit 
a broad T cell response, both in terms of specificity and clonal 
diversity (59–61). The success of future cancer immunotherapies 
based on these technologies will depend on the ability to fine-
tune the desired T cell responses toward specific tumor epitopes. 
Our data suggest that malleable structural features of the target 
neoepitope/MHC complex can be harnessed to achieve such 
a fine-tuning. Thus, our characterization of recurring, T  cell-
reactive neoepitopes together with their HLA specificities and 
molecular determinants of stability provide new screening tools 
and therapeutic targets to enable the development of personal-
ized immunotherapies against NBL tumors.
MaTerials anD MeThODs
nBl sample Data collection and ProTecT 
analysis
One hundred NBL sequencing trios (normal and tumor DNA-
seq, and tumor RNA-seq) were downloaded from the National 
Cancer Institute Genomics Data Commons (NCI-GDC) using 
the GDC Data Transfer Tool. Samples were all downloaded 
in BAM format and then converted back to the native paired 
FASTQ format using the Picard SamToFastq module. Some 
of the RNA-seq BAM files had reads in the pair mapped with 
separate read groups. These files were converted to FASTQ using 
an in-house python script.1 We processed the samples from raw 
FASTQ trios to neoepitopes prediction at a rate of ~6 h/sample 
on four Microsoft Azure machines (Supplementary Data S1 in 
Supplementary Material). MHC haplotypes for MHC class I and 
MHC class II are called from the sequencing data using PHLAT 
(62). The haplotype for a sample is decided based on a consensus 
decision of the three input haplotypes. Somatic point mutations 
were called using a panel of five mutation callers, MuTECT (63), 
MuSE (64), RADIA (65), SomaticSniper (66), and Strelka (67). 
Since most mutation callers are DNA centric, we allow mutations 
rejected by up to two of the callers through this first filter. The vcf 
of first-pass mutants is subjected to SNPEff (68) using indexes 
1 https://github.com/arkal/random/process_rgs.py.
generated from the GENCODE v19 annotations for GRCh37 
(69). The accepted mutations are further filtered more stringently 
using an in-house tool, Transgene,2 before being translated into 
mutant peptides. Library construction for sequencing can induce 
artificial oxidation of guanine bases (OxoG) (70) caused by high-
energy sonication. These OxoG bases pair with thymine during 
PCR instead of their regular pairing partner, cytosine. This results 
in low allele fraction G>T or C>A substitutions seen predomi-
nantly in read 1 or read 2, respectively, in the FASTQ. Transgene 
filters variants arising solely form read 1 or read 2 in the align-
ment, and low allele-fraction mutants (<0.1 allele fraction) with 
no RNA-seq coverage. Since non-expressed proteins will never be 
picked up by the adaptive immune system, we filter events having 
low RNA-seq coverage. A mutation is filtered if the position has 
no evidence in the RNA (unexpressed ALT allele), there are reads 
spanning across, but none covering the position (splice variant), 
or if the gene is unexpressed. Filtered mutants are translated into 
peptides of length 2n − 1 for n = (9, 10, 15) using the GENCODE 
protein coding translations corresponding to the annotation 
used. Transcript-specific peptides are generated to account for 
known splice variants. The peptides generated by transgene are 
tested for binding against the inferred HLA haplotypes using 
the IEDB suite of MHC-I and MHC-II epitope predictors.3 Each 
2n − 1-mer input peptide yields n calls for each allele in the HLA 
haplotype, for each n = (9, 10) for MHCI and n = 15 for MHC-II. 
Each call represents a combined consensus percent score of 
the peptide from a number of IEDB algorithms that have been 
trained on that MHC allele. These methods include an artificial 
neural network, a stabilized matrix method, a method that uses 
binding motif obtained from Combinatorial libraries, etc., and 
each method returns the percent rank of the input peptide:MHC 
combination versus a background set generated by the IEDB. The 
consensus score for a call is the median of the scores across all 
methods for that call. Peptides having a consensus percent score 
of greater than 5% (i.e., binders worse than the top 5% of the 
background set) are filtered as non-binders. Peptides having a 
consensus percent rank of greater than 5% (i.e., binders worse 
than the top 5% of a background set) are filtered as non-binders. 
The rank of the self-peptide for each filtered mutant is calculated 
using the same method. Peptides are grouped by the mutation 
and transcript(s) of origin into ImmunoActive Regions (IARs), 
i.e., regions likely to produce a peptide that will stimulate the 
immune system. IARs are ranked based on the affinity of the 
best contained binder, expression of the transcript(s) of origin, 
the promiscuity of the region (the predicted number of MHCs 
stimulated by peptides in the IAR), and the number of 10-mers in 
the IAR overlapping a 9-mer that binds to the same MHC as the 
10-mer, with similar affinity. In the initial pilot, RNA-seq BAMs 
from six primary:relapsed pairs of samples were downloaded 
from the GDC and run through a reduced version of the pipeline 
using VCF files generated from the supplementary data from 
Eleveld et al. (16) containing predicted mutations. MHC haplo-
types for these samples were decided based on the consensus calls 
from the primary and relapsed RNA-seq. All samples were run 
2 https://github.com/arkal/Transgene.
3 http://tools.iedb.org/mhci/.
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through version 2.3.2 of the ProTECT pipeline (freely available 
Docker version at https://quay.io/repository/ucsc_cgl/protect) 
on Microsoft Azure standard_G5 (32 CPUs, 448GB RAM, 6TB 
disk) or standard_D15_v2 (20 CPUS, 140GB RAM, 1TB disk).
recombinant Protein expression and 
Purification
HLA-B*15:01 and HLA-A*01:01 genes containing a BirA tag 
were cloned into pET24+ plasmids and provided to us by the 
NIH Tetramer Core facility. For all in vitro experiments and the 
preparation of purified molecules for X-ray crystallography, we 
used soluble versions of the MHC heavy chain that lacks the 
BirA tag. Site directed mutagenesis to remove the BirA tag was 
performed using a QuikChange Lightning Multi-Site Kit (Agilent 
#210515) following the manufacturer’s instructions. Resulting 
DNAs encoding HLA-B*15:01 (heavy chain), HLA-A*01:01 
(heavy chain), and human β2M (light chain) were transformed 
into E. coli BL21-DE3 (Novagen), expressed as inclusion bodies, 
and refolded using previously described methods (22). Briefly, E. 
coli growths with autoinduction (71) were pelleted by centrifuga-
tion and resuspended with 25  mL BugBuster (MilliporeSigma 
#70584) per liters of culture. Cell lysate was sonicated and subse-
quently pelleted by centrifugation (5,180 × g for 20 min at 4°C) to 
collect inclusion bodies. Inclusion bodies were resuspended with 
25 mL of wash buffer (100 mM Tris pH 8, 2 mM EDTA, and 0.01% 
v/v deoxycholate), sonicated, and centrifuged again. Inclusion 
bodies were further resuspended in 25 mL of TE buffer (100 mM 
Tris pH 8, 2 mM EDTA) sonicated, and centrifuged. Following 
this, inclusion bodies are solubilized with 11 mL of resuspension 
buffer (100 mM Tris pH 8, 2 mM EDTA, 0.1 mM DTT, and 6 M 
guanidine–HCl). Solubilized inclusion bodies of heavy chain and 
light chain were mixed in a 1:3 M ratio and then added dropwise 
over 2 days to 1 L of refolding buffer (100 mM Tris pH 8, 2 mM 
EDTA, 0.4 M arginine HCl, 4.9 mM l-glutathione reduced, and 
0.57 mM l-glutathione oxidized) containing 10 mg of synthetic 
peptide (Biopeptik). Refolding was performed for 4 days at 4°C 
without stirring then the sample was exhaustively dialyzed into 
SEC buffer (25  mM Tris pH 8 and 150  mM NaCl). Following 
this, the sample was concentrated with Labscale TFF system 
to 100 mL and further concentrated to a final volume of 5 mL 
using an Amicon Ultra-15 Centrifugal 10 kDa cutoff Filter Unit 
(Millapore Sigma). Purification was performed using SEC on a 
HiLoad 16/600 Superdex 75 pg with running buffer of 25 mM Tris 
pH 8 and 150 mM NaCl, followed by anion exchange chromatog-
raphy using a mono Q 5/50 GL column and a 0–100% gradient 
of buffer A (25 mM Tris pH 8 and 50 mM NaCl) and buffer B 
(25 mM Tris pH 8 and 1 M NaCl). Finally, the purified protein 
was exhaustively buffer exchanged into 20 mM sodium phosphate 
pH 7.2 and 50 mM NaCl. The final sample was validated using 
LC–MS on an LTQ-Orbitrap Velos Pro MS instrument to confirm 
the presence of bound peptide.
Mhc Tetramerization
HLA-B*15:01 containing BirA tag was refolded together with 
either synthetically produced AQDIYRASY or AQDIYRASYY 
peptide (Biopeptik) and purified following methods described 
earlier. Purified protein was concentrated to 0.5  mg/mL and 
500 µg was biotinylated using a BirA biotin-protein ligase bulk 
reaction kit (Avidity Cat no. bulk BirA) following the manufac-
turer’s instructions. An SDS-PAGE gel shift assay was performed 
to confirm the efficiency of the biotinylation reaction according 
to previously published protocols (72). The biotinylated protein 
sample was concentrated to 200 µL and split into two approxi-
mately 200 µg aliquots. For streptavidin–PE tetramers, 31.8 µL 
of 1  mg/mL of streptavidin-R-phycoerythrin (Prozyme cat no. 
PJRS25) was added 10 times in intervals of 10 min. For streptavi-
din–APC tetramers, 17.1 µL of 1 mg/mL streptavidin–allophyco-
cyanin (Prozyme cat no. PJ27S) was added 10 times in intervals of 
10 min. The final tetramer samples were stored at 4°C.
Protein crystallization
Purified HLA-B*15:01/AQDIYRASY, HLA-B*15:01/AQDIYRASYY, 
and HLA-A*01:01/AQDIYRASYY complexes lacking a BirA 
biotinylation tag were used for crystallization. Proteins were 
concentrated to 10–12 mg/mL in 50 mM NaCl, 25 mM Tris pH 
8.0, and crystal trays were set up using 1:1 protein-to-buffer ratio 
at room temperature. For HLA-B*15:01/AQDIYRASY, small 
crystals appeared in initial screening using molecular dimen-
sions JCSG-plus screen after 3 days in 100 mM HEPES pH 6.5 
and 20% PEG 6000 and they were further optimized. Diffraction 
quality crystals were harvested and incubated from above condi-
tions plus Al’s oil as a cryoprotectant and flash-frozen in liquid 
nitrogen before data collection. Diamond shaped diffraction 
quality crystals of HLA-B15:01/AQDIYRASYY were grown in 
crystallization buffer containing 100  mM HEPES, 2  M ammo-
nium sulfate, and 2–4% PEG 400. Diffraction quality crystals of 
HLA-A*01:01/AQDIYRASYY were grown in 0.18 M magnesium 
chloride, 0.09 M sodium HEPES pH 7.5, 27% (v/v) PEG400, and 
10% (v/v) glycerol. Crystals were flash-frozen in liquid nitrogen 
in a buffer containing the crystallization condition supplemented 
with 25% glycerol. All crystals used in this study were grown using 
the hanging drop vapor diffusion method. Data were collected 
from single crystals under cryogenic condition at Advanced Light 
Source (beam lines 8.3.1 and 5.0.1). Diffraction images were 
indexed, integrated, and scaled using Mosflm and Scala in the 
CCP4 package (73). Structures were determined by Phaser (74) 
using a previous structure of HLA-B*15:01 (PDB ID 1XR8) (25) 
and HLA-A*01:01 (PDB ID 1W72) (75) as search models. Model 
building and refinement were performed using COOT (76) and 
Phenix (77), respectively.
Differential scanning Fluorimetry
All DSF experiments were performed using an Applied Biosystems 
ViiA qPCR machine with excitation and emission wavelengths 
at 470  nm and 569  nm respectively, according to previously 
described protocols (23). Each sample was run in triplicates of 
50 μL total volume using a 96 well-plate format. Proteins were 
buffer exchanged into the assay buffer which was 20 mM sodium 
phosphate at pH 7.2 and 50 mM NaCl. Individual wells contained 
a final concentration of 7 µM of the respective proteins and 10× 
SYPRO orange dye (ThermoFisher). To determine thermal sta-
bility of each sample, the temperature incrementally increased 
at a scan rate of 1°C/min from 25 to 95°C. Data analysis was 
performed using GraphPad Prism. Melting temperatures (Tm) 
were determined by fitting the melting curves to a Boltzmann 
sigmoidal fit.
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Modeling Mhc Molecules and extracting 
Peptide/Mhc-Binding energies
The solved X-ray structure of HLA-B*15:01/AQDIYRASY com-
plex was used to generate a structural model for HLA-B*15:01/
ARDIYRASY using single-point mutagenesis in Pymol (The 
PyMOL Molecular Graphics System, Version 1.8 Schrödinger, 
LLC.) All Dunbrack rotamers (78) for the Arg2 side chain 
were considered manually, and the rotamer giving the lowest 
strain was used in our final structural model in Figure S6A in 
Supplementary Material. Peptide/MHC-binding energies were 
computed using the Rosetta software suite.4 Average binding 
energies of residue-specific interactions were calculated using the 
residue_energy_breakdown protocol in Rosetta.
To assess the ability of our ALK neoepitopes to bind to other 
HLA alleles, we performed homology-based structure simulations 
and computed p/MHC-binding energies in  silico. An outline of 
our method is presented in Figure 4. Three-dimensional structural 
modeling and computation of p/MHC-binding affinities were 
performed using the Rosetta software suite (see text footnote 4). 
To carry out the modeling of homologous HLA alleles, we used 
RosettaCM protocol (50). The process of modeling high-resolution 
protein structures using RosettaCM primarily requires, that is, the 
sequence of the homolog is aligned with the sequence of a related 
known structure. It is subsequently followed by the generation of 
predicted 3D structures using restraints guided by a Monte Carlo 
sampling strategy. After performing the structure simulations of 
HLA alleles using our HLA-B*15:01 X-ray structure as a template, 
we carried out local refinement of the peptide and the MHC-
binding groove. We kept backbone atoms fixed while allowing for 
conformational freedom of side-chain residues. The MHC-binding 
groove was defined by the HLA residues that were within 3.5 Å 
of the peptide. Local structure refinement allowed minimization 
of steric clashes introduced by the RosettaCM protocol. In addi-
tion, we refined only the peptide and the MHC-binding groove 
of the models to avoid noise that the full-atom refinement might 
introduce while trying to minimize the energy landscape at other 
regions and hence, making it difficult to extract accurate p/MHC-
binding energies. At the local refinement stage, we generated a pool 
of refined structures from which we sampled low binding energy 
(or high-binding affinity) structures. Average binding energy was 
evaluated using the Rosetta energy function talaris2014 (79, 80). 
The computation of binding energies was performed in the fol-
lowing steps: (1) we trimmed the MHC PDB file to remove the 
β2m and α3 domains, such that only the α1/α2 domains that form 
the peptide-binding groove were retained. (2) We performed local 
refinement of the MHC-binding groove and the peptide using 
Rosetta’s relax protocol (81), which allows the region of focus to 
be in the local optimum of the Rosetta force field. Using the relax 
protocol, we obtained a pool of 100 locally refined models. (3) 
We computed the binding energies of the relaxed models using 
the InterfaceAnalyzer protocol (79, 82) by separating the MHC 
and the peptide energy contributions and subtracting them from 
the energy of the bound p/MHC (30). (4) We then selected the 
lowest 10 binding energy models and report their average binding 
4 https://www.rosettacommons.org.
energies. The sequence identity score was computed using the 
BLOSUM62 matrix (33) because most of the HLA alleles (68%) 
showed up to 62% sequence similarity. To perform the simulation, 
we obtained the HLA sequences from European Bioinformatics 
Institute’s IPD-IMGT/HLA Database (29). We used ClustalOmega 
(83) to perform multiple sequence alignment of the HLA alleles 
before converting the alignment to Rosetta’s internal alignment 
format for homology modeling. Kullback–Leibler sequence logos 
were generated as previously described (84). Rosetta simulations 
were performed at the UCSC Baker cluster using 13 compute 
nodes with 32 cores per compute node (AMD Opteron(tm), 
2.4 GHz Processor 6378). The total time used to model 2,904 HLA 
sequences was approximately 20,000 core hours.
PBMc staining
206 Cryopreserved PBMCs (CTL) from two healthy independent 
non-pooled HLA-B*15:01 donors were thawed and rested in phe-
nol red free RPMI-1640 media supplemented with 10% FBS, 1% 
l-glut, and 1% Pen/Strep at 37°C for at least 1 h. Four independent 
PBMC staining experiments were run for each donor. 36 PBMCs 
were used for the nonamer/HLA-B*15:01, decamer/HLA-B*15:01, 
and SARS/HLA-B*15:01 double staining experiment. 116 PBMCs 
were used for the decamer/HLA-B*15:01-APC and nonamer/HLA-
B*15:01-PE experiment. After the resting period, cells were washed 
with 1× PBS, followed by staining with 4 µL of each tetramer, 5% 
CO2 for 10 min. An aqua amine-reactive dye (Invitrogen # L34957) 
was added for 10 min to assess cell viability, followed by the addi-
tion of an antibody cocktail (CD14, CD19, CD4, CD8) to stain for 
surface markers for an additional 20 min. The cells were washed 
with FACS buffer (PBS containing 0.1% sodium azide and 1% BSA) 
and sorted using an Aria C Flow Cytometer. Analysis of percent-
age of reactive CD8+ T cells was performed following gating on 
forward/side scattering for live lymphocytes (FSC+/SSC−), gating 
on Qdot− for live cells and gating on CD4−/CD8+ T cells.
DaTa aVailaBiliTY
The refined coordinates and structure factors for the X-ray struc-
tures of HLA-B*15:01/AQDIYRASY, HLA-B*15:01/AQDIYRASYY, 
and HLA-A*01:01/AQDIYRASYY complexes have been depos-
ited in the Protein Data Bank (www.rcsb.org) with PDB IDs 5TXS, 
5VZ5, and 6AT9, respectively. The ProTECT pipeline is available 
for use under the Apache License v2.0 for academic users (https://
github.com/BD2KGenomics/protect).
eThics sTaTeMenT
All patients provided informed consent for analysis of health 
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5.3 The pediatric NBL study supplementary
The supplementary data pdf contains a lot of information that was conducted by the Sgourakis
and Maris Groups. The relevant printable sections of the supplement are provided below. Sup-
plementary data sheets 1, 2, and 3 are too large to add to this thesis as pdf formatted tables. The
full supplementary (including supplementary data sheets 1, 2, and 3) can be obtained from the
Frontiers in Immunology website.
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Supplementary Tables 
 
Protein:Mutation Immuno Active Region 
Samples with 
Expressed 
Mutation 
Therapeutic  
MHC-I Allele  
(Frequency in 
Population) 
Counts  
in 
COSMIC 
Primary Relapse 
ALK:R1275Q* AKIGDFGMA[R/Q]DIYRASYYR 5 1 HLA-B*15:01 (0.06) HLA-A*02:01 (0.20) 101 
ALK:F1174L LMEALIISK[F/L]NHQNIVRCI 3 0 HLA-B*44:03 (0.02) 144 
ALK:F1174I LMEALIISK[F/I]NHQNIVRCI 1 0 HLA-B*13:02 (0.01) 7 
ZNF717:Q716E NVENPFIRR[Q/E]IFRSIKVFT 3 0 HLA-B*07:02 (0.03) 0 
KCNJ12:E378K LPSANSFCY[E/K]NELAFLSRD 2 2 HLA-A*23:01 (0.01) 0 
ITGB2:I712T AIVGGTVAG[I/T]VLIGILLLV 2 0 HLA-A*02:01 (0.02) 0 
USP6:R69W TAREAKKIR[R/W]EMTRTSKWM 2 0 HLA-A*24:02 (0.38) HLA-C*04:01 (0.15) 0 
TSC22D1:T961K LFPLKVLPL[T/K]TPLVDGEDE 2 0 HLA-C*03:03 (0.04) HLA-C*04:01 (0.15) 0 
NRAS:Q61K LLDILDTAG[Q/K]EEYSAMRDQ 1 1 HLA-A*01:01 (0.04) 1287 
 
Supplementary Table 1. ProTECT analysis of 100 primary and 6 primary:relapsed pairs of 
TARGET NBL samples. The first column shows identified proteins (in italics) with their 
respective mutation observed in tumors. The second column shows the ImmunoActive Region of 
each protein with the format [X /Y] in bold denoting wild-type and mutant amino acids, 
respectively. The third column shows the number of samples with the expressed mutation in 
primary and relapsed patients. The fourth column shows the best predicted therapeutic MHC allele, 
which is defined as either an allele shared by samples expressing the same mutation or an allele 
with the best predicted binding score. For each allele, the frequency (denoted in parenthesis) is in 
Caucasian populations. The fifth column shows counts in COSMIC that refer to the sum total of 
unique entries in the Catalog of Somatic Mutations in Cancer database (1) for each mutation.  
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Chapter 6
Conclusion
6.1 Introduction
This thesis describes my doctoral work on the prediction of therapeutically significant neoepi-
topes for Adoptive Cell- and Vaccine-based immunotherapies. ProTECT has a lot of potential
clinical utility, especially given the current traction of the entire immuno-oncology field.
6.2 Chapters
In Chapter 1, I introduced the basics of Immunology, the workings of the adaptive immune
system, and I talked about how doctors can potentially treat cancers similar to bacterial and
viral infections. I described the current state of immuno-oncology and talked about the methods
that are being used to treat cancers using immunological agents. I highlight the importance
of T-cell based targeted immunotherapies as being less harmful to the patient due to higher
specificity of the tumor as a target. I talk about the limitations of these methods in terms of
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time and complexity, explaining how shortlisting targets will lead to faster therapies for patients
diagnosed with cancer.
In Chapter 2, I talk about my work on a workflow engine developed at UCSC. Run-
ning bioinformatics pipelines at scale can be resource intensive and using a smart, efficient
workflow engine can allow a user to run pipelines faster, with fewer interruptions. Making large
workflows easy to run enables researchers to broaden their sample sets and look at their data
with a broader scope. Providing support for cloud deployment further broadens the horizons
of researchers, making extremely large analyses possible at affordable costs. It also supports
collaboration across institutions given the increase in cloud acceptance by Institutional Review
Boards.
In Chapter 3, I describe a tool I wrote at UCSC, TransGene. TransGene allows a user
to translate any combination of genomic variants (SNV, INDEL, or fusion-genes) into peptides
that can be used to identify neoepitopes in a tumor. TransGene was developed since there was
no available tool that could perform this task, limiting the automation of a neoepitope prediction
workflow. TransGene served as the backbone of the ProTECT pipeline, translating the mutants
called from a consensus of callers into peptides that could be processed by the IEDB suite of
pMHC prediction tools.
Chapter 4 describes the bulk of my work as a Ph.D. candidate. The ProTECT pipeline
is a one-of-a-kind end-to-end workflow to process sequencing data and produce a ranked list of
neoepitopes of therapeutic significance. The workflow is entirely self-contained and automated,
allowing the user to run the whole pipeline without any manual intervention. This allows clinical
labs without a bioinformatics team to analyze in-house data that cannot be shared outside their
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institution (A common problem faced by a number of hospitals worldwide). The pipeline is
entirely reproducible through the magic of Docker, so the results from running ProTECT on a
remote server are guaranteed to be the same as the results I would obtain on a local machine.
This gives an external institution the confidence that their data is receiving the same treatment
as that given by a trained bioinformatician. I demonstrate the efficiency and automation of
ProTECT on a 326 sample cohort and compare ProTECT’s performance with published tools.
Using ProTECT, I predict potentially broadly therapeutic neoepitopes in the PRAD cohort that
can benefit a large subpopulation of PRAD patients.
Chapter 5 describes a real-world application of the ProTECT pipeline. I analyzed
the data from 106 pediatric Neuroblastoma samples and identified 2 peptides from a hotspot
mutant that is predicted to bind to an MHC molecule that is sufficiently common in Caucasian
populations. The predicted combinations were validated as good binders using Biochemical
methods and were also predicted to be recognized by CD8+ T-cells. This suggests the mutation
is broadly immunotherapeutically significant.
6.3 Discussion
Vaccine-based and Adoptive cell-therapies are quickly demonstrating their superiority as the fu-
ture of cancer therapies in terms of durable regression of treated cancers, and due to the reduced
cytotoxicity associated with these therapies as compared to traditional chemo- and radiation-
based therapies. Rapid administration of these therapies to terminally diagnosed cancer pa-
tients could save many lives, however these therapies are currently time consuming. Reduction
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in the time taken to go from a patient biopsy to a cure is essential for these therapies to become
clinically viable as the standard-of-care.
This thesis described an open-source, portable method to predict and rank neoepitopes
in a tumor sample that will be relevant for existing and future neoepitope-driven immunother-
apies. The method was used to identify a potentially therapeutic epitope in a high-risk cohort
of pediatric cancers with poor prognosis. When it is published, ProTECT will be only the third
published tool for neoepitope discovery. As the only fully portable and automated one, I hope
ProTECT will be adopted by a larger audience in the field of cancer immunotherapy. Since
ProTECT works with FASTQ reads straight off a sequencer, it serves as an easy-to use utility
for labs with minimal bioinformatics support.
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Chapter 7
Appendix
7.1 Figures
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Figure 7.1: A screengrab of the ‘Contributors’ tab on the BD2KGenomics/toil repository from
the date of my first commit to the time of publication showing my substantial contribution.
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